data_2m7x_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m7x _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.741 0.305 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.809 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.4 tt . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.839 0.352 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.853 0.359 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.458 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.84 0.352 . . . . 0.0 110.504 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.569 ' CD2' ' H ' ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.756 0.312 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.773 0.321 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 2.0 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.745 0.307 . . . . 0.0 110.53 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.458 ' CG2' ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.458 ' N ' ' CG2' ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.786 0.327 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.926 0.393 . . . . 0.0 110.632 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.852 0.358 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.798 0.332 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.739 0.304 . . . . 0.0 110.637 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.837 0.351 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.819 0.342 . . . . 0.0 110.634 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.45 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.804 0.335 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.498 ' CD1' ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.807 0.337 . . . . 0.0 110.251 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.498 ' N ' ' CD1' ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.81 0.338 . . . . 0.0 110.577 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.677 ' HG ' ' H ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.677 ' H ' ' HG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.454 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.859 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.402 ' CG2' ' O ' ' A' ' 138' ' ' ALA . 15.9 tt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.747 0.308 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.445 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 CA--C 1.526 0.056 0 CA-C-O 120.724 0.297 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.749 0.309 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.2 tp . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.362 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.78 0.324 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.522 ' N ' ' CD2' ' A' ' 125' ' ' LEU . 3.8 mm? . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 0.0 OUTLIER -95.62 162.61 23.74 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.396 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -69.78 173.36 11.1 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.557 2.171 . . . . 0.0 112.021 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.29 -24.09 37.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.58 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -85.01 19.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.556 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -68.24 -41.77 80.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.573 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.92 -58.18 9.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp -62.28 -34.44 76.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.56 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt -64.14 -39.27 84.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 144' ' ' THR . 89.6 m -60.87 -64.51 0.93 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.625 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.3 OUTLIER 74.36 -36.79 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.583 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.507 ' H ' ' C ' ' A' ' 142' ' ' THR . 67.9 p -97.59 -107.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.579 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.471 ' N ' ' OG1' ' A' ' 144' ' ' THR . 0.0 OUTLIER -156.82 163.17 25.95 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.461 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -38.42 160.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.642 2.228 . . . . 0.0 112.209 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -71.22 -19.43 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.584 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.9 mp -69.06 -38.25 78.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.598 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.9 -33.11 64.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.537 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.05 -30.91 71.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.51 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.88 -42.4 73.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.555 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 153' ' ' VAL . 6.8 mt -71.35 -31.42 43.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.617 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 152' ' ' ILE . 18.3 t 57.59 155.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.587 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.649 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 -179.902 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 126' ' ' PHE . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.072 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.421 ' C ' ' O ' ' A' ' 125' ' ' LEU . 1.9 m-85 -32.92 98.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.343 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.274 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -83.75 162.71 14.22 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 122.207 1.938 . . . . 0.0 112.144 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -69.98 -53.25 18.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 15.6 tt -61.57 113.32 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.539 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -68.37 -20.23 64.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.602 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -61.02 -64.67 0.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.584 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.24 -31.03 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.583 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.4 tt -64.18 -33.38 62.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.403 ' O ' ' O ' ' A' ' 143' ' ' SER . 1.2 m -60.93 -20.76 62.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.603 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.403 ' O ' ' O ' ' A' ' 142' ' ' THR . 6.5 t -61.06 -137.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.549 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 59.1 114.81 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.593 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.07 162.61 51.37 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.541 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.77 -84.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.503 2.135 . . . . 0.0 112.106 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.445 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 84.1 t -148.08 2.07 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.585 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 5.9 mt -69.11 -41.79 76.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 36.7 t -55.87 -27.7 53.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.97 -37.16 85.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.613 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 22.9 mt -69.84 -34.3 73.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.608 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.419 ' O ' ' C ' ' A' ' 153' ' ' VAL . 72.3 mt -71.53 -50.46 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.604 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.419 ' C ' ' O ' ' A' ' 152' ' ' ILE . 1.2 m 31.54 86.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.401 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.681 0.277 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.486 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.2 p90 -135.21 69.53 69.32 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.496 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -80.33 -178.84 4.75 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.777 2.318 . . . . 0.0 112.225 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -74.28 -39.6 62.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 95.1 mt -41.68 -33.52 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.536 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -68.28 -45.54 72.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -61.07 -51.1 70.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.548 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.16 -31.68 72.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.48 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt -64.15 -22.34 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 23.8 m -61.0 -37.99 84.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.593 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 3.8 t 47.5 -143.66 0.37 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.556 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.3 p -47.79 132.08 14.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.545 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.99 162.58 28.25 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.503 ' C ' ' H ' ' A' ' 148' ' ' LEU . 39.8 Cg_endo -69.71 -166.87 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.575 2.183 . . . . 0.0 112.08 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.3 m -54.99 -6.87 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.563 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.503 ' H ' ' C ' ' A' ' 146' ' ' PRO . 3.5 tp -69.1 -19.91 64.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.525 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -55.96 -22.23 25.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.588 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . 0.423 ' O ' ' O ' ' A' ' 153' ' ' VAL . . . -66.02 -20.16 66.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.2 tt -69.78 -57.81 4.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.602 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.42 -30.35 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.492 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 150' ' ' ALA . 59.6 t -94.31 133.59 34.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.531 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.624 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.07 0 CA-C-O 120.843 0.354 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 21.5 t80 60.4 60.5 3.76 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.672 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.85 -172.02 1.01 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.676 2.251 . . . . 0.0 112.177 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -76.41 -51.52 11.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.524 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.4 mt -76.83 110.95 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 131' ' ' PHE . 25.7 p30 -68.25 -27.31 66.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.602 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.484 ' N ' ' OD1' ' A' ' 130' ' ' ASN . 41.0 m-85 -61.01 -53.05 61.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.588 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt -62.05 -34.64 76.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.604 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.414 ' O ' ' OG1' ' A' ' 142' ' ' THR . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.458 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp -64.05 -40.92 90.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' A' ' 139' ' ' GLY . 0.6 OUTLIER -60.86 -65.23 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.669 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.522 ' HG ' ' N ' ' A' ' 144' ' ' THR . 95.3 p 42.6 -112.38 0.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.555 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.522 ' N ' ' HG ' ' A' ' 143' ' ' SER . 9.2 t -92.38 164.42 13.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.561 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 41.85 73.94 0.83 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.446 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 147' ' ' VAL . 36.4 Cg_exo -56.97 -66.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.776 2.317 . . . . 0.0 112.077 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.424 ' C ' ' O ' ' A' ' 146' ' ' PRO . 31.3 m 33.12 39.89 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.204 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.0 -22.14 64.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.491 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.1 p -56.18 -25.89 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.544 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.91 -46.92 76.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.573 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 13.4 mt -69.88 -34.08 73.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.537 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.4 ' O ' ' O ' ' A' ' 153' ' ' VAL . 93.1 mt -71.41 -19.97 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.582 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 152' ' ' ILE . 1.5 t 56.54 162.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.552 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.738 0.304 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -138.71 162.68 51.58 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.441 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.11 156.87 61.42 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.592 2.195 . . . . 0.0 112.114 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -84.91 -55.01 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.609 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.455 ' CD1' ' H ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -76.51 111.87 13.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.449 179.941 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.32 -32.03 71.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.708 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -60.9 -67.21 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.509 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp -62.28 -23.38 66.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.504 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.569 ' CD2' ' H ' ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt -64.15 -23.51 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.455 ' O ' ' CB ' ' A' ' 143' ' ' SER . 40.6 p -60.91 -21.71 63.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.619 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 78.4 130.89 0.05 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.49 179.933 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.1 150.57 37.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.619 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.407 ' O ' ' OD2' ' A' ' 145' ' ' ASP . 6.8 p-10 41.3 67.16 3.2 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.84 175.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.736 2.29 . . . . 0.0 112.152 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 53.1 t -100.85 -32.34 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.623 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mt -69.13 -63.68 1.02 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -24.6 38.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.19 -25.86 67.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.53 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.82 -34.44 73.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.578 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.2 mm -71.41 -21.61 21.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.575 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 69.0 t 53.33 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.628 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.606 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.992 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 39.0 tp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.783 0.325 . . . . 0.0 110.408 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.515 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 83.4 t80 -171.4 60.81 0.32 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -74.14 149.63 41.37 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.76 2.307 . . . . 0.0 112.09 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 38.4 mt-30 -84.27 -59.27 2.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.558 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 81.7 mt -56.5 105.59 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.56 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -68.41 -33.18 73.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -61.06 -20.7 62.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.554 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt -62.17 -33.15 73.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt -64.08 -29.59 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 61.8 m -61.02 -27.95 68.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.559 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 69.0 m -44.67 157.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.542 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.416 ' OG1' ' N ' ' A' ' 145' ' ' ASP . 59.8 p -139.52 -106.38 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.59 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.418 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -87.1 163.15 41.38 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.493 -179.982 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.418 ' O ' ' O ' ' A' ' 145' ' ' ASP . 83.9 Cg_exo -38.38 162.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.612 0 C-N-CA 122.699 2.266 . . . . 0.0 112.191 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.5 p -137.75 151.99 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.11 -27.64 65.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.83 -20.16 14.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . 0.454 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -66.1 -19.93 66.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.546 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 4.6 tp -69.81 -60.24 2.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.546 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 74.6 mt -71.51 -65.42 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.568 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.512 ' CG1' ' H ' ' A' ' 154' ' ' GLY . 2.2 t 65.41 -139.62 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.592 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.512 ' H ' ' CG1' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.7 0.286 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.9 p90 -134.96 69.31 70.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.602 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.2 174.52 11.32 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.872 2.381 . . . . 0.0 112.171 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.505 ' C ' ' H ' ' A' ' 130' ' ' ASN . 3.8 tp-100 -79.29 -36.51 39.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.547 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -64.97 3.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.575 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.505 ' H ' ' C ' ' A' ' 128' ' ' GLN . 54.4 t30 -68.27 -30.14 69.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.585 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -60.98 -45.0 96.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.604 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp -62.08 -20.25 63.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.574 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt -64.08 -40.61 89.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -28.4 68.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.597 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 144' ' ' THR . 0.2 OUTLIER -99.88 167.92 10.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.568 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.42 ' O ' ' O ' ' A' ' 143' ' ' SER . 10.9 p -43.22 167.85 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.589 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.09 161.05 41.82 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.415 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.17 159.14 55.02 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.493 2.129 . . . . 0.0 112.072 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 47.3 t -96.43 95.57 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.07 -28.13 66.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.51 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 11.5 t -55.93 -20.45 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -33.63 76.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.588 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.87 -24.31 63.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.439 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 3.4 mm -71.32 -68.77 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.526 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 154' ' ' GLY . 45.7 t 50.99 93.8 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.616 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.527 0.81 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.795 0.331 . . . . 0.0 110.62 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 27.1 t80 59.84 67.22 1.82 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.608 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -47.87 175.14 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.856 2.371 . . . . 0.0 112.073 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -68.75 -68.8 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.4 mm -84.33 135.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 27.0 m-20 -68.21 -42.93 79.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.626 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -61.09 -68.68 0.29 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.49 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp -62.06 -26.57 68.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.554 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 2.0 tp -64.22 -35.73 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 p -60.96 -27.5 68.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.516 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.89 -49.64 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.516 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 55.0 p -82.45 162.89 21.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -99.17 161.29 25.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.446 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 145' ' ' ASP . 82.0 Cg_exo -38.45 163.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.673 2.249 . . . . 0.0 112.117 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -49.91 171.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.18 -29.9 67.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.498 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 4.4 m -55.95 -39.0 71.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.646 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -20.42 66.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.714 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.4 tp -69.92 -40.04 75.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.558 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.42 -65.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.567 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.67 ' CG2' ' H ' ' A' ' 154' ' ' GLY . 9.7 p -94.62 -141.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.247 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.67 ' H ' ' CG2' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.851 0.358 . . . . 0.0 110.63 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 42.1 t80 53.5 60.86 11.4 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.581 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.04 124.48 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.619 2.213 . . . . 0.0 112.099 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 129' ' ' ILE . 3.3 tt0 -85.14 -19.78 31.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.584 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.461 ' CG2' ' H ' ' A' ' 130' ' ' ASN . 2.7 mp -44.83 170.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.533 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.461 ' H ' ' CG2' ' A' ' 129' ' ' ILE . 4.5 p-10 -67.51 -19.7 65.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -59.68 -19.85 52.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.602 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt -61.96 -34.14 75.57 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.53 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.458 ' CG2' ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.458 ' N ' ' CG2' ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.12 -37.83 80.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.445 ' O ' ' CB ' ' A' ' 143' ' ' SER . 2.6 m -61.0 -24.06 65.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.58 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.445 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.7 OUTLIER 76.83 -57.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.556 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 43.8 p -69.37 156.15 39.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.538 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -154.88 163.2 25.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.453 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 145' ' ' ASP . 81.0 Cg_exo -38.53 163.34 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.584 2.189 . . . . 0.0 112.3 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -45.41 168.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 9.8 mp -68.98 -20.11 64.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.638 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.91 -40.67 73.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.562 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -20.04 66.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.518 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.2 tt -69.88 -58.7 3.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.565 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.404 ' O ' ' O ' ' A' ' 153' ' ' VAL . 69.1 mt -71.45 -23.77 23.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.601 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.46 ' CG1' ' N ' ' A' ' 154' ' ' GLY . 58.0 t 55.21 165.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.877 0.37 . . . . 0.0 110.619 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.496 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 179.48 -47.24 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.921 179.726 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 39.1 Cg_exo -57.68 169.13 2.65 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.141 1.894 . . . . 0.0 112.014 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -81.3 -39.97 24.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.465 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.6 mt -71.12 -17.57 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.469 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -20.76 64.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.475 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.421 ' CD1' ' C ' ' A' ' 131' ' ' PHE . 3.4 t80 -60.77 -25.21 66.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.587 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.27 -66.09 0.59 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.386 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.41 ' O ' ' OG1' ' A' ' 142' ' ' THR . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt -64.11 -25.52 38.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.41 ' OG1' ' O ' ' A' ' 138' ' ' ALA . 3.2 m -60.88 -31.44 70.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.584 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 12.0 t 53.11 -95.96 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.586 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 29.9 p -67.16 114.15 5.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -81.95 161.49 60.49 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.891 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 145' ' ' ASP . 80.5 Cg_exo -38.27 162.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.682 2.255 . . . . 0.0 112.214 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 36.8 t -99.8 -52.37 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.541 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mt -69.12 -55.35 10.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.588 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.97 -19.53 12.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.657 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 -20.31 66.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.771 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 9.2 mp -69.85 -48.99 56.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.644 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 21.9 pt -71.57 -30.12 37.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.599 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -47.65 142.37 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.523 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.638 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.996 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.882 0.372 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 48.62 67.23 4.71 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.563 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -47.71 176.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.812 2.342 . . . . 0.0 112.131 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -78.15 -41.71 33.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.624 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -71.68 96.37 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.579 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -68.35 -29.71 68.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.561 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -60.97 -64.86 0.81 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.528 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp -62.04 -31.77 72.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.632 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt -64.15 -53.33 44.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.648 ' HG1' ' H ' ' A' ' 143' ' ' SER . 12.5 p -61.01 -67.03 0.44 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.59 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.648 ' H ' ' HG1' ' A' ' 142' ' ' THR . 1.3 p 56.85 158.71 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.578 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 75.0 p -95.2 92.49 6.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.539 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.94 161.08 80.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.42 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.86 -169.74 0.3 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.487 2.124 . . . . 0.0 112.046 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 2.2 t -137.17 -26.93 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.566 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.1 -34.81 75.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.544 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 t -55.95 -40.38 73.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.582 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -25.98 67.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.52 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -69.95 -44.82 68.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.369 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.51 -57.39 7.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.579 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.1 t -142.44 120.49 7.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.547 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.739 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.772 0.32 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 1.3 p90 -137.34 70.43 54.26 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.584 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -49.58 -175.43 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 122.805 2.337 . . . . 0.0 112.052 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -75.67 -22.42 56.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.619 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 72.4 mt -43.32 102.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.534 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -68.37 -21.22 64.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -61.07 -29.22 69.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.604 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp -62.17 -21.69 65.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.586 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -24.92 36.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.415 ' HG1' ' HG1' ' A' ' 144' ' ' THR . 80.9 p -60.96 -20.84 62.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.565 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 71.2 47.74 0.39 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.592 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.534 ' CG2' ' H ' ' A' ' 145' ' ' ASP . 5.9 m -84.66 -130.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.563 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.534 ' H ' ' CG2' ' A' ' 144' ' ' THR . 2.1 m-20 -154.08 67.34 5.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.579 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.402 ' O ' ' O ' ' A' ' 145' ' ' ASP . 52.3 Cg_exo -47.81 -178.23 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.804 2.336 . . . . 0.0 112.077 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.42 ' O ' ' CG2' ' A' ' 147' ' ' VAL . 27.8 m -91.91 66.25 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.627 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 6.7 mt -69.05 -21.38 64.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.563 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 3.4 p -55.96 -21.18 19.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.575 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.04 -42.12 89.97 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.593 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 tp -69.83 -43.02 72.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.424 HG22 HD13 ' A' ' 152' ' ' ILE . 9.1 mm -71.45 -25.28 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.534 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 2.3 t 63.98 112.49 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.62 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.965 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.748 0.309 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.26 162.65 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.539 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -69.84 88.8 0.54 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.594 2.196 . . . . 0.0 112.072 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' A' ' 129' ' ' ILE . 1.8 tt0 -55.75 -19.96 13.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.627 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.421 ' O ' ' O ' ' A' ' 128' ' ' GLN . 0.2 OUTLIER -56.3 -160.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.65 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -68.33 -19.93 64.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.544 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.86 -19.87 60.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.661 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.06 -28.71 69.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.633 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.08 -30.01 48.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 2.3 m -60.99 -23.22 65.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.598 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 28.2 m -48.13 129.99 15.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.592 ' CG2' ' H ' ' A' ' 145' ' ' ASP . 0.5 OUTLIER -145.87 -99.35 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.678 179.942 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.592 ' H ' ' CG2' ' A' ' 144' ' ' THR . 97.9 m-20 -138.05 67.16 48.0 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.582 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -47.82 138.92 20.0 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.86 2.373 . . . . 0.0 112.081 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.7 m -66.27 147.3 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.601 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.1 -23.14 63.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.541 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.84 -21.48 20.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.547 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.96 -31.16 71.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.632 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.519 ' CD2' ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -69.93 -29.34 66.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.458 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 22.5 mt -71.4 -51.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.548 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 13.1 m -91.27 19.26 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.518 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.941 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.701 0.286 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 43.4 60.7 10.79 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.557 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.98 -168.62 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.711 2.274 . . . . 0.0 112.139 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.425 ' O ' ' N ' ' A' ' 130' ' ' ASN . 3.4 mt-30 -81.02 -62.21 1.73 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.502 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -68.18 66.09 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.593 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.425 ' N ' ' O ' ' A' ' 128' ' ' GLN . 0.1 OUTLIER -68.22 -22.4 64.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.544 -179.943 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -60.42 3.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.579 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt -62.14 -19.92 63.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.637 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 144' ' ' THR . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm -64.08 -62.67 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 3.1 m -60.98 -69.96 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.572 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 t -172.3 58.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.529 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 139' ' ' GLY . 0.2 OUTLIER 56.83 164.23 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.57 -179.996 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -76.21 161.07 76.45 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.433 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.09 174.75 8.47 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.483 2.122 . . . . 0.0 112.143 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.407 ' O ' ' CG2' ' A' ' 147' ' ' VAL . 31.1 m -98.14 67.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.2 -33.48 73.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.411 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' SER . . . . . 0.4 ' O ' ' N ' ' A' ' 153' ' ' VAL . 14.2 p -55.91 -20.53 16.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.535 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.07 -32.05 73.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . 0.486 ' CD1' ' N ' ' A' ' 151' ' ' LEU . 9.5 mp -69.78 -62.21 1.47 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.558 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 12.0 tt -71.37 -20.38 21.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.511 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.4 ' N ' ' O ' ' A' ' 149' ' ' SER . 2.3 t 64.83 141.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.624 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.671 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.955 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.6 tp . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.798 0.333 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 16.6 t80 63.83 60.29 1.75 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.62 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.7 144.79 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.693 2.262 . . . . 0.0 112.064 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.401 ' O ' ' N ' ' A' ' 130' ' ' ASN . 38.1 tt0 -81.79 -59.38 2.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.567 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.1 pt -66.21 72.81 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.575 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 128' ' ' GLN . 24.5 t-20 -68.28 -23.85 64.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.507 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -60.88 -22.37 64.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.15 -57.22 12.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.6 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt -64.05 -26.39 40.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.2 m -61.14 -38.94 88.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 27.0 t -138.07 125.51 21.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.597 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -167.13 17.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.73 60.3 4.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.635 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.68 107.48 2.41 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.738 2.292 . . . . 0.0 112.117 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.63 13.38 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.528 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.1 mt -69.07 -34.5 75.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.587 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 6.2 m -55.78 -33.65 64.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.591 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.98 -20.25 66.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.569 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.86 -51.13 35.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.629 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . 0.455 ' O ' ' C ' ' A' ' 153' ' ' VAL . 97.5 mt -71.43 -38.89 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.555 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' A' ' 152' ' ' ILE . 9.3 p 22.32 51.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 124.06 0.85 . . . . 0.0 111.994 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.729 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.942 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.1 mt . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.838 0.352 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -147.78 67.33 10.22 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.491 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -47.87 107.77 0.15 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.907 2.405 . . . . 0.0 112.082 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -78.74 -20.35 50.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.577 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.78 141.66 17.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.583 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -68.37 -20.18 64.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.555 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.95 -68.46 0.31 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.557 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp -62.14 -25.94 68.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.45 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp -64.1 -44.02 97.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.426 ' O ' ' CB ' ' A' ' 143' ' ' SER . 16.1 m -60.95 -27.46 68.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.608 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 75.44 139.36 0.06 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.569 -179.992 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.4 p -141.39 -20.24 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.603 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.0 162.64 51.32 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.466 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.76 169.73 18.23 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.587 2.191 . . . . 0.0 112.058 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.401 ' O ' ' CG1' ' A' ' 147' ' ' VAL . 12.5 p -95.53 115.38 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.559 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 10.8 mp -69.07 -20.48 64.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.603 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 p -55.84 -22.16 23.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.59 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.08 -35.92 81.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.56 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 29.0 mt -69.8 -35.99 75.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.453 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.8 mt -71.36 -50.77 38.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.566 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.72 133.62 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.924 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.873 0.368 . . . . 0.0 110.543 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 41.57 62.24 7.3 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -75.76 102.2 1.57 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.791 2.327 . . . . 0.0 112.194 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 14.0 tt0 -82.01 -68.9 0.66 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 4.2 tt -83.75 -21.43 8.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.583 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.425 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.3 t30 -68.26 -20.56 64.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.596 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -60.99 -57.54 12.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt -62.22 -37.4 85.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.553 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.425 ' N ' ' O ' ' A' ' 130' ' ' ASN . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt -64.25 -56.21 17.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 143' ' ' SER . 20.9 p -61.01 -69.36 0.24 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.611 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.438 ' OG ' ' N ' ' A' ' 144' ' ' THR . 1.2 t 166.46 172.04 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.567 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.438 ' N ' ' OG ' ' A' ' 143' ' ' SER . 4.7 t -165.0 42.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.574 ' N ' ' CD ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -92.12 -43.33 0.36 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.051 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 145' ' ' ASP . 58.0 Cg_endo -86.66 -87.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.796 2.331 . . . . 0.0 112.223 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.617 ' CG1' ' H ' ' A' ' 148' ' ' LEU . 10.7 p -168.1 -120.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.45 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.617 ' H ' ' CG1' ' A' ' 147' ' ' VAL . 1.9 pp -68.58 -19.87 64.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.579 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.9 t -55.1 -49.3 72.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.503 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.3 -22.85 66.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.494 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.87 -25.35 63.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.607 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.8 mt -71.37 -64.1 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.606 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.408 ' CG2' ' O ' ' A' ' 153' ' ' VAL . 7.9 p -172.97 58.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.597 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.963 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.825 0.345 . . . . 0.0 110.469 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 57.4 65.85 3.33 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.599 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -46.1 157.4 0.4 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.831 2.354 . . . . 0.0 112.161 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.43 ' O ' ' O ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -84.95 -19.89 31.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.637 ' CG1' ' H ' ' A' ' 130' ' ' ASN . 0.6 OUTLIER -60.14 -145.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.233 -179.88 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.637 ' H ' ' CG1' ' A' ' 129' ' ' ILE . 3.3 t30 -68.71 -26.29 65.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.753 0.311 . . . . 0.0 110.547 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.83 -19.8 60.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.531 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.498 ' CD1' ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -61.78 -18.58 60.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.251 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.498 ' N ' ' CD1' ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . 0.422 ' O ' ' OG ' ' A' ' 143' ' ' SER . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.14 -29.84 48.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 99.0 m -61.09 -20.19 62.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.422 ' OG ' ' O ' ' A' ' 140' ' ' CYS . 6.3 p -41.92 158.16 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.584 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -46.04 112.86 0.53 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.571 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.426 ' N ' ' CD ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER 178.72 -50.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.896 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.426 ' CD ' ' N ' ' A' ' 145' ' ' ASP . 73.1 Cg_endo -83.0 176.1 7.91 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 122.28 1.987 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 31.1 m -42.56 119.6 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.604 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.07 -19.93 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.526 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.78 -24.23 34.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.57 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.16 -24.03 66.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.615 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.86 -32.42 70.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.469 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 87.6 mt -71.43 -68.54 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.523 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.9 t -55.14 115.64 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.564 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.682 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.473 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 2.8 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.744 0.307 . . . . 0.0 110.487 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' A' ' 125' ' ' LEU . 91.1 m-85 -156.24 60.52 2.35 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.638 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.83 179.0 6.09 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.714 2.276 . . . . 0.0 112.143 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -51.61 -69.99 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.6 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.408 ' CG2' ' O ' ' A' ' 129' ' ' ILE . 4.6 tt -83.01 81.16 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.559 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.36 -20.04 64.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.497 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -61.03 -65.68 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.61 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt -62.14 -56.03 22.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.577 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.677 ' HG ' ' H ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.677 ' H ' ' HG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.454 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp -64.08 -29.18 46.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 2.4 t -60.94 -26.88 67.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.605 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' SER . . . . . 0.422 ' O ' ' OG1' ' A' ' 144' ' ' THR . 0.7 OUTLIER -99.36 -162.1 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.598 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.422 ' OG1' ' O ' ' A' ' 143' ' ' SER . 16.3 p 55.17 106.98 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.477 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.449 ' CB ' ' CD ' ' A' ' 146' ' ' PRO . 0.9 OUTLIER -175.27 -64.73 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.937 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 145' ' ' ASP . 16.8 Cg_endo -58.48 170.11 2.67 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.168 1.912 . . . . 0.0 112.034 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.453 ' O ' ' CG2' ' A' ' 147' ' ' VAL . 7.2 p -90.83 5.01 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.572 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 tp -69.19 -39.78 78.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.429 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 93.2 p -55.7 -44.83 77.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.546 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -27.06 67.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.501 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.1 tt -69.91 -55.34 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.598 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.42 -20.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.553 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.503 ' CG1' ' H ' ' A' ' 154' ' ' GLY . 2.6 t 63.31 -135.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.562 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.503 ' H ' ' CG1' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.81 0.338 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.505 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 178.72 -47.15 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.76 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.505 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 32.8 Cg_exo -56.68 -149.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.23 1.953 . . . . 0.0 112.117 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -62.78 -19.8 64.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 46.8 mt -50.03 -28.98 4.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.554 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -68.23 -46.28 70.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.479 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -61.03 -21.08 63.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.452 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.12 -31.82 72.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.457 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.402 ' CG2' ' O ' ' A' ' 138' ' ' ALA . 15.9 tt -64.07 -27.08 41.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.0 p -61.02 -20.11 62.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.58 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.7 t -42.93 -91.6 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.578 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 27.6 p -141.34 -108.91 0.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.523 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 30.8 m-20 -155.5 60.11 2.41 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' O ' ' N ' ' A' ' 148' ' ' LEU . 55.3 Cg_endo -73.56 -167.54 0.38 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.715 2.277 . . . . 0.0 112.055 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.436 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 7.5 p -45.59 94.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.532 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.448 ' N ' ' O ' ' A' ' 146' ' ' PRO . 1.0 OUTLIER -68.99 -20.12 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.564 -179.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.87 -20.75 16.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.523 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -33.83 76.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.584 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.82 -27.06 64.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.561 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 1.3 mm -71.55 -43.68 71.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.427 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 97.2 t -62.0 -8.46 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.579 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.696 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.997 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 9.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.79 0.329 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.439 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.1 p90 -152.87 67.26 6.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.589 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.8 133.66 22.37 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 122.816 2.344 . . . . 0.0 112.076 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -79.26 -51.36 9.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' A' ' 129' ' ' ILE . 16.8 tt -51.64 101.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.519 179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -68.37 -19.91 64.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.626 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -60.82 -69.91 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.627 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.1 -31.64 72.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.569 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.445 ' CD1' ' N ' ' A' ' 141' ' ' ILE . 1.7 mp -63.96 -32.59 57.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 7.7 m -61.16 -31.88 71.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.507 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 1.3 t 172.42 132.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.561 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 145' ' ' ASP . 0.9 OUTLIER -87.78 102.66 14.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.52 -179.964 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 144' ' ' THR . 0.8 OUTLIER -30.46 95.57 0.08 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 O-C-N 123.768 0.668 . . . . 0.0 111.514 -179.883 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -54.52 119.02 5.72 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.11 1.874 . . . . 0.0 111.863 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.9 t -87.2 98.81 7.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mp -69.34 -29.07 66.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.581 179.919 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' SER . . . . . 0.417 ' H ' ' HG ' ' A' ' 149' ' ' SER . 0.7 OUTLIER -55.86 -29.83 60.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.634 -179.931 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.95 -40.74 91.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.571 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.78 -42.85 73.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.566 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.1 mt -71.45 -58.1 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.553 179.981 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 36.8 t -101.7 136.11 35.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.543 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.98 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.53 ' CG ' ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.793 0.33 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.53 ' H ' ' CG ' ' A' ' 125' ' ' LEU . 71.5 m-85 -138.8 60.74 19.82 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.649 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.432 ' O ' ' N ' ' A' ' 129' ' ' ILE . 55.9 Cg_endo -74.09 -168.05 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.683 2.256 . . . . 0.0 112.086 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . 0.473 ' C ' ' H ' ' A' ' 130' ' ' ASN . 7.5 mp0 -41.98 -25.45 0.06 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.556 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.432 ' N ' ' O ' ' A' ' 127' ' ' PRO . 18.7 mt -74.52 40.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.553 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.473 ' H ' ' C ' ' A' ' 128' ' ' GLN . 0.5 OUTLIER -68.31 -20.2 64.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.546 179.986 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.88 -33.93 73.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.562 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt -62.2 -42.1 98.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.486 -179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -22.76 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 70.5 p -60.98 -23.02 65.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.585 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.8 t -73.36 52.98 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.511 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.14 -47.3 5.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.588 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -145.0 67.12 13.27 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.532 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.514 ' C ' ' H ' ' A' ' 148' ' ' LEU . 52.0 Cg_exo -47.64 179.97 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.809 2.34 . . . . 0.0 112.199 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -61.99 -0.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.514 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . 0.514 ' H ' ' C ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -69.04 -49.63 55.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.423 179.997 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.95 -19.98 14.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.629 179.897 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . 0.475 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -65.95 -25.0 66.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.655 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.22 -57.26 5.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 5.7 mt -71.46 -65.6 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.623 -179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' A' ' 150' ' ' ALA . 2.1 t 66.3 153.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.603 -179.92 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.982 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.805 0.336 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 68.4 t80 44.63 60.74 12.28 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.617 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.11 131.77 15.84 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.674 2.249 . . . . 0.0 112.055 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -63.17 -43.43 98.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.533 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.2 mt -55.33 99.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.562 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -68.34 -22.86 64.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -60.91 -31.68 71.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.655 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.06 -26.0 68.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.57 179.925 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.2 tp -64.1 -23.41 33.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 72.5 m -61.03 -66.84 0.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.594 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.0 m 42.75 77.07 0.07 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.589 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -138.31 -30.49 0.78 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.573 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.442 ' C ' ' H ' ' A' ' 147' ' ' VAL . 48.1 t0 -145.45 60.53 6.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.567 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.85 20.16 0.39 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.753 2.302 . . . . 0.0 112.174 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.456 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 61.2 t -77.08 48.69 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.606 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 3.1 mt -69.03 -20.38 64.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.564 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.93 -35.89 67.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.597 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.0 -20.17 66.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.59 179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.2 tt -69.74 -57.87 4.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.55 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.7 mt -71.44 -39.21 70.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.511 -179.909 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.44 142.57 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.628 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.978 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.489 ' CG ' ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.769 0.319 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.489 ' H ' ' CG ' ' A' ' 125' ' ' LEU . 22.7 t80 -163.98 62.79 1.08 Allowed Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.623 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.7 -165.32 0.29 Allowed 'Trans proline' 0 C--N 1.306 -1.701 0 C-N-CA 122.691 2.26 . . . . 0.0 112.2 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -82.48 -48.77 10.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.782 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -85.16 32.2 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.095 0.474 . . . . 0.0 110.59 179.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -68.15 -25.88 65.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -60.97 -50.46 73.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.615 179.919 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp -62.05 -27.26 68.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt -64.08 -20.91 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.4 m -60.92 -66.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.7 p -87.18 139.55 30.45 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.525 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 65.89 159.77 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.494 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -150.59 60.54 4.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.653 -179.917 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.94 148.65 40.83 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.795 2.33 . . . . 0.0 112.045 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.1 m -99.73 -18.32 6.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.61 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.11 -63.66 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.597 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 75.3 m -55.93 -29.87 60.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.06 -20.03 66.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.555 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.8 tp -69.81 -19.96 63.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.493 -179.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 1.9 tp -71.42 -20.91 21.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.521 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.4 p -43.79 151.39 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.593 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 179.965 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.809 0.337 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.411 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 75.1 t80 -162.3 67.23 1.97 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.79 111.32 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.806 2.337 . . . . 0.0 112.071 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -84.92 -20.08 31.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.52 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -56.41 137.57 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -68.35 -20.06 64.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.59 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -60.86 -65.72 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.09 -22.35 65.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.556 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt -64.12 -42.23 94.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 19.0 p -61.01 -22.5 64.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.577 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.5 t 60.99 78.24 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.7 t -172.23 150.33 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.503 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 43.23 67.25 3.81 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.593 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -47.76 137.67 21.02 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.773 2.315 . . . . 0.0 112.123 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 63.3 t -77.01 154.77 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.606 179.96 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 10.8 mp -69.07 -46.17 68.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.59 -179.958 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.94 -43.84 77.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.548 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -22.73 66.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.542 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.0 tp -69.87 -22.6 63.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.528 -179.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 31.7 mt -71.47 -64.51 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.574 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -138.09 145.28 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.569 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.99 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.741 0.305 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.809 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.57 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 138' ' ' ALA . 11.4 tt . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.839 0.352 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.853 0.359 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.421 ' N ' HD12 ' A' ' 135' ' ' LEU . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.84 0.352 . . . . 0.0 110.504 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.73 ' H ' HD23 ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 134' ' ' SER . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.756 0.312 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.773 0.321 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 137' ' ' ILE . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.497 ' O ' HG22 ' A' ' 137' ' ' ILE . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.497 HG22 ' O ' ' A' ' 134' ' ' SER . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.506 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.506 HG22 ' O ' ' A' ' 138' ' ' ALA . 2.0 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.745 0.307 . . . . 0.0 110.53 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.625 HG23 ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.625 ' N ' HG23 ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.786 0.327 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.926 0.393 . . . . 0.0 110.632 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.505 HG22 ' O ' ' A' ' 134' ' ' SER . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.852 0.358 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 134' ' ' SER . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.798 0.332 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.739 0.304 . . . . 0.0 110.637 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.837 0.351 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.819 0.342 . . . . 0.0 110.634 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.804 0.335 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 138' ' ' ALA . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.436 ' HB2' ' O ' ' A' ' 134' ' ' SER . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 1.026 HD13 ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.807 0.337 . . . . 0.0 110.251 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 1.026 ' N ' HD13 ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.696 ' O ' HG22 ' A' ' 137' ' ' ILE . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.696 HG22 ' O ' ' A' ' 134' ' ' SER . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.81 0.338 . . . . 0.0 110.577 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.501 ' N ' ' OG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.556 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.859 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.796 HG22 ' O ' ' A' ' 138' ' ' ALA . 15.9 tt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.747 0.308 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 137' ' ' ILE . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.502 HG22 ' O ' ' A' ' 134' ' ' SER . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 CA--C 1.526 0.056 0 CA-C-O 120.724 0.297 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.749 0.309 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' ALA . 1.2 tp . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.362 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.78 0.324 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.549 ' N ' HD22 ' A' ' 125' ' ' LEU . 3.8 mm? . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 0.0 OUTLIER -95.62 162.61 23.74 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.396 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -69.78 173.36 11.1 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.557 2.171 . . . . 0.0 112.021 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.29 -24.09 37.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.58 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -85.01 19.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.556 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -68.24 -41.77 80.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.573 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.92 -58.18 9.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp -62.28 -34.44 76.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.56 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt -64.14 -39.27 84.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 144' ' ' THR . 89.6 m -60.87 -64.51 0.93 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.625 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.3 OUTLIER 74.36 -36.79 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.583 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.473 ' H ' ' C ' ' A' ' 142' ' ' THR . 67.9 p -97.59 -107.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.579 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.471 ' N ' ' OG1' ' A' ' 144' ' ' THR . 0.0 OUTLIER -156.82 163.17 25.95 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.461 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -38.42 160.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.642 2.228 . . . . 0.0 112.209 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.48 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.2 OUTLIER -71.22 -19.43 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.584 179.914 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.9 mp -69.06 -38.25 78.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.598 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.9 -33.11 64.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.537 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.05 -30.91 71.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.51 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.88 -42.4 73.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.555 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 153' ' ' VAL . 6.8 mt -71.35 -31.42 43.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.617 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 152' ' ' ILE . 18.3 t 57.59 155.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.587 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.405 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.649 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 126' ' ' PHE . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.072 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.421 ' C ' ' O ' ' A' ' 125' ' ' LEU . 1.9 m-85 -32.92 98.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.343 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.274 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -83.75 162.71 14.22 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 122.207 1.938 . . . . 0.0 112.144 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -69.98 -53.25 18.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.604 HG23 ' O ' ' A' ' 129' ' ' ILE . 15.6 tt -61.57 113.32 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.539 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -68.37 -20.23 64.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.602 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -61.02 -64.67 0.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.584 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.24 -31.03 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.583 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.57 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 138' ' ' ALA . 11.4 tt -64.18 -33.38 62.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.403 ' O ' ' O ' ' A' ' 143' ' ' SER . 1.2 m -60.93 -20.76 62.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.603 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.403 ' O ' ' O ' ' A' ' 142' ' ' THR . 6.5 t -61.06 -137.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.549 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 59.1 114.81 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.593 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.07 162.61 51.37 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.541 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.77 -84.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.503 2.135 . . . . 0.0 112.106 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.651 ' O ' HG12 ' A' ' 147' ' ' VAL . 84.1 t -148.08 2.07 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.585 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 5.9 mt -69.11 -41.79 76.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 36.7 t -55.87 -27.7 53.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.621 ' O ' HG13 ' A' ' 153' ' ' VAL . . . -65.97 -37.16 85.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.613 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 22.9 mt -69.84 -34.3 73.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.608 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.419 ' O ' ' C ' ' A' ' 153' ' ' VAL . 72.3 mt -71.53 -50.46 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.604 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.621 HG13 ' O ' ' A' ' 150' ' ' ALA . 1.2 m 31.54 86.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.401 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.681 0.277 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.486 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.2 p90 -135.21 69.53 69.32 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.496 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -80.33 -178.84 4.75 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.777 2.318 . . . . 0.0 112.225 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -74.28 -39.6 62.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 95.1 mt -41.68 -33.52 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.536 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -68.28 -45.54 72.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -61.07 -51.1 70.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.548 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.16 -31.68 72.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.48 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt -64.15 -22.34 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 23.8 m -61.0 -37.99 84.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.593 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 3.8 t 47.5 -143.66 0.37 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.556 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.3 p -47.79 132.08 14.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.545 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.99 162.58 28.25 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.479 ' C ' ' H ' ' A' ' 148' ' ' LEU . 39.8 Cg_endo -69.71 -166.87 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.575 2.183 . . . . 0.0 112.08 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.3 m -54.99 -6.87 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.563 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.479 ' H ' ' C ' ' A' ' 146' ' ' PRO . 3.5 tp -69.1 -19.91 64.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.525 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -55.96 -22.23 25.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.588 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.423 ' O ' ' O ' ' A' ' 153' ' ' VAL . . . -66.02 -20.16 66.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.467 ' O ' HD23 ' A' ' 151' ' ' LEU . 1.2 tt -69.78 -57.81 4.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.602 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.593 HG23 HG23 ' A' ' 153' ' ' VAL . 6.4 tt -71.42 -30.35 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.492 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.593 HG23 HG23 ' A' ' 152' ' ' ILE . 59.6 t -94.31 133.59 34.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.531 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.624 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.07 0 CA-C-O 120.843 0.354 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 21.5 t80 60.4 60.5 3.76 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.672 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.85 -172.02 1.01 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.676 2.251 . . . . 0.0 112.177 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 33.5 tt0 -76.41 -51.52 11.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.524 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.4 mt -76.83 110.95 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 131' ' ' PHE . 25.7 p30 -68.25 -27.31 66.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.602 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.484 ' N ' ' OD1' ' A' ' 130' ' ' ASN . 41.0 m-85 -61.01 -53.05 61.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.588 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt -62.05 -34.64 76.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.604 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.421 ' N ' HD12 ' A' ' 135' ' ' LEU . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.05 -40.92 90.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -60.86 -65.23 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.669 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 144' ' ' THR . 95.3 p 42.6 -112.38 0.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.555 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.442 ' N ' ' OG ' ' A' ' 143' ' ' SER . 9.2 t -92.38 164.42 13.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.561 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 41.85 73.94 0.83 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.446 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 147' ' ' VAL . 36.4 Cg_exo -56.97 -66.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.776 2.317 . . . . 0.0 112.077 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.424 ' C ' ' O ' ' A' ' 146' ' ' PRO . 31.3 m 33.12 39.89 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.204 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.0 -22.14 64.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.491 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.1 p -56.18 -25.89 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.544 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.91 -46.92 76.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.573 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 13.4 mt -69.88 -34.08 73.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.537 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.4 ' O ' ' O ' ' A' ' 153' ' ' VAL . 93.1 mt -71.41 -19.97 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.582 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 152' ' ' ILE . 1.5 t 56.54 162.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.552 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.738 0.304 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -138.71 162.68 51.58 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.441 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.11 156.87 61.42 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.592 2.195 . . . . 0.0 112.114 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -84.91 -55.01 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.609 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.548 HD13 ' H ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -76.51 111.87 13.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.449 179.941 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.32 -32.03 71.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.708 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -60.9 -67.21 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.509 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp -62.28 -23.38 66.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.504 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.73 ' H ' HD23 ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 134' ' ' SER . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt -64.15 -23.51 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.455 ' O ' ' CB ' ' A' ' 143' ' ' SER . 40.6 p -60.91 -21.71 63.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.619 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 78.4 130.89 0.05 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.49 179.933 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.1 150.57 37.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.619 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.407 ' O ' ' OD2' ' A' ' 145' ' ' ASP . 6.8 p-10 41.3 67.16 3.2 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.84 175.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.736 2.29 . . . . 0.0 112.152 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 53.1 t -100.85 -32.34 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.623 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mt -69.13 -63.68 1.02 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -24.6 38.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.19 -25.86 67.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.53 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.82 -34.44 73.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.578 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.2 mm -71.41 -21.61 21.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.575 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 154' ' ' GLY . 69.0 t 53.33 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.628 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.56 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.606 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 39.0 tp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.783 0.325 . . . . 0.0 110.408 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.515 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 83.4 t80 -171.4 60.81 0.32 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -74.14 149.63 41.37 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.76 2.307 . . . . 0.0 112.09 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 38.4 mt-30 -84.27 -59.27 2.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.558 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 81.7 mt -56.5 105.59 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.56 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -68.41 -33.18 73.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -61.06 -20.7 62.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.554 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt -62.17 -33.15 73.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt -64.08 -29.59 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 61.8 m -61.02 -27.95 68.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.559 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 69.0 m -44.67 157.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.542 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.46 ' OG1' ' N ' ' A' ' 145' ' ' ASP . 59.8 p -139.52 -106.38 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.59 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.46 ' N ' ' OG1' ' A' ' 144' ' ' THR . 0.0 OUTLIER -87.1 163.15 41.38 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.493 -179.982 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.418 ' O ' ' O ' ' A' ' 145' ' ' ASP . 83.9 Cg_exo -38.38 162.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.612 0 C-N-CA 122.699 2.266 . . . . 0.0 112.191 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.5 p -137.75 151.99 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.11 -27.64 65.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.83 -20.16 14.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.454 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -66.1 -19.93 66.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.546 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 4.6 tp -69.81 -60.24 2.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.546 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.476 ' C ' HG23 ' A' ' 153' ' ' VAL . 74.6 mt -71.51 -65.42 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.568 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 154' ' ' GLY . 2.2 t 65.41 -139.62 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.592 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.587 ' H ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.7 0.286 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.9 p90 -134.96 69.31 70.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.602 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.2 174.52 11.32 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.872 2.381 . . . . 0.0 112.171 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.479 ' C ' ' H ' ' A' ' 130' ' ' ASN . 3.8 tp-100 -79.29 -36.51 39.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.547 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -64.97 3.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.575 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.479 ' H ' ' C ' ' A' ' 128' ' ' GLN . 54.4 t30 -68.27 -30.14 69.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.585 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -60.98 -45.0 96.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.604 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp -62.08 -20.25 63.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.574 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 137' ' ' ILE . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt -64.08 -40.61 89.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -28.4 68.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.597 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 144' ' ' THR . 0.2 OUTLIER -99.88 167.92 10.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.568 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.44 ' H ' HG23 ' A' ' 144' ' ' THR . 10.9 p -43.22 167.85 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.589 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.09 161.05 41.82 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.415 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.17 159.14 55.02 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.493 2.129 . . . . 0.0 112.072 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 47.3 t -96.43 95.57 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.07 -28.13 66.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.51 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 11.5 t -55.93 -20.45 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.685 ' O ' HG23 ' A' ' 153' ' ' VAL . . . -66.11 -33.63 76.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.588 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.87 -24.31 63.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.439 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 3.4 mm -71.32 -68.77 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.526 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.685 HG23 ' O ' ' A' ' 150' ' ' ALA . 45.7 t 50.99 93.8 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.616 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.527 0.81 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.795 0.331 . . . . 0.0 110.62 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 27.1 t80 59.84 67.22 1.82 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.608 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -47.87 175.14 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.856 2.371 . . . . 0.0 112.073 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -68.75 -68.8 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.4 mm -84.33 135.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 27.0 m-20 -68.21 -42.93 79.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.626 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -61.09 -68.68 0.29 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.49 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp -62.06 -26.57 68.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.554 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.497 ' O ' HG22 ' A' ' 137' ' ' ILE . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.497 HG22 ' O ' ' A' ' 134' ' ' SER . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.506 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.506 HG22 ' O ' ' A' ' 138' ' ' ALA . 2.0 tp -64.22 -35.73 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 p -60.96 -27.5 68.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.516 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.89 -49.64 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.516 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 55.0 p -82.45 162.89 21.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -99.17 161.29 25.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.446 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 145' ' ' ASP . 82.0 Cg_exo -38.45 163.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.673 2.249 . . . . 0.0 112.117 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.407 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.7 OUTLIER -49.91 171.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.893 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.18 -29.9 67.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.498 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 4.4 m -55.95 -39.0 71.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.646 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -20.42 66.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.714 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.4 tp -69.92 -40.04 75.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.558 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.42 -65.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.567 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.91 HG22 ' H ' ' A' ' 154' ' ' GLY . 9.7 p -94.62 -141.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.247 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.91 ' H ' HG22 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.851 0.358 . . . . 0.0 110.63 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 42.1 t80 53.5 60.86 11.4 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.581 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.04 124.48 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.619 2.213 . . . . 0.0 112.099 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 129' ' ' ILE . 3.3 tt0 -85.14 -19.78 31.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.584 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.664 HG22 ' N ' ' A' ' 130' ' ' ASN . 2.7 mp -44.83 170.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.533 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.664 ' N ' HG22 ' A' ' 129' ' ' ILE . 4.5 p-10 -67.51 -19.7 65.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -59.68 -19.85 52.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.602 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt -61.96 -34.14 75.57 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.53 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.625 HG23 ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.625 ' N ' HG23 ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.12 -37.83 80.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.445 ' O ' ' CB ' ' A' ' 143' ' ' SER . 2.6 m -61.0 -24.06 65.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.58 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.445 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.7 OUTLIER 76.83 -57.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.556 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 43.8 p -69.37 156.15 39.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.538 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -154.88 163.2 25.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.453 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 145' ' ' ASP . 81.0 Cg_exo -38.53 163.34 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.584 2.189 . . . . 0.0 112.3 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.3 OUTLIER -45.41 168.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 148' ' ' LEU . 9.8 mp -68.98 -20.11 64.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.638 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.91 -40.67 73.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.562 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -20.04 66.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.518 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.462 ' O ' HD23 ' A' ' 151' ' ' LEU . 1.2 tt -69.88 -58.7 3.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.565 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.404 ' O ' ' O ' ' A' ' 153' ' ' VAL . 69.1 mt -71.45 -23.77 23.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.601 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.629 HG12 ' N ' ' A' ' 154' ' ' GLY . 58.0 t 55.21 165.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.629 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.877 0.37 . . . . 0.0 110.619 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.496 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 179.48 -47.24 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.921 179.726 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 39.1 Cg_exo -57.68 169.13 2.65 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.141 1.894 . . . . 0.0 112.014 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -81.3 -39.97 24.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.465 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.6 mt -71.12 -17.57 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.469 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -20.76 64.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.475 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.421 ' CD1' ' C ' ' A' ' 131' ' ' PHE . 3.4 t80 -60.77 -25.21 66.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.587 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.27 -66.09 0.59 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.386 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt -64.11 -25.52 38.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 3.2 m -60.88 -31.44 70.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.584 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 12.0 t 53.11 -95.96 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.586 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 29.9 p -67.16 114.15 5.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -81.95 161.49 60.49 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.891 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 145' ' ' ASP . 80.5 Cg_exo -38.27 162.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.682 2.255 . . . . 0.0 112.214 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.41 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 36.8 t -99.8 -52.37 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.541 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mt -69.12 -55.35 10.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.588 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.97 -19.53 12.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.657 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 147' ' ' VAL . . . -65.24 -20.31 66.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.771 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 151' ' ' LEU . 9.2 mp -69.85 -48.99 56.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.644 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 21.9 pt -71.57 -30.12 37.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.599 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -47.65 142.37 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.523 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.638 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.996 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.882 0.372 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 48.62 67.23 4.71 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.563 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -47.71 176.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.812 2.342 . . . . 0.0 112.131 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -78.15 -41.71 33.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.624 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -71.68 96.37 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.579 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -68.35 -29.71 68.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.561 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -60.97 -64.86 0.81 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.528 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp -62.04 -31.77 72.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.632 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.505 HG22 ' O ' ' A' ' 134' ' ' SER . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt -64.15 -53.33 44.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.42 ' O ' ' O ' ' A' ' 143' ' ' SER . 12.5 p -61.01 -67.03 0.44 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.59 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 142' ' ' THR . 1.3 p 56.85 158.71 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.578 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 75.0 p -95.2 92.49 6.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.539 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.94 161.08 80.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.42 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.86 -169.74 0.3 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.487 2.124 . . . . 0.0 112.046 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 2.2 t -137.17 -26.93 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.566 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.497 ' H ' HD23 ' A' ' 148' ' ' LEU . 0.2 OUTLIER -69.1 -34.81 75.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.544 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 t -55.95 -40.38 73.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.582 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -25.98 67.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.52 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -69.95 -44.82 68.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.369 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.51 -57.39 7.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.579 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.1 t -142.44 120.49 7.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.547 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.739 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.772 0.32 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.552 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 1.3 p90 -137.34 70.43 54.26 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.584 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -49.58 -175.43 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 122.805 2.337 . . . . 0.0 112.052 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -75.67 -22.42 56.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.619 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 72.4 mt -43.32 102.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.534 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -68.37 -21.22 64.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -61.07 -29.22 69.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.604 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp -62.17 -21.69 65.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.586 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 134' ' ' SER . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -24.92 36.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 80.9 p -60.96 -20.84 62.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.565 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 71.2 47.74 0.39 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.592 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.574 HG22 ' H ' ' A' ' 145' ' ' ASP . 5.9 m -84.66 -130.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.563 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.574 ' H ' HG22 ' A' ' 144' ' ' THR . 2.1 m-20 -154.08 67.34 5.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.579 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.402 ' O ' ' O ' ' A' ' 145' ' ' ASP . 52.3 Cg_exo -47.81 -178.23 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.804 2.336 . . . . 0.0 112.077 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.647 ' O ' HG23 ' A' ' 147' ' ' VAL . 27.8 m -91.91 66.25 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.627 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 6.7 mt -69.05 -21.38 64.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.563 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 3.4 p -55.96 -21.18 19.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.575 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.04 -42.12 89.97 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.593 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 tp -69.83 -43.02 72.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' VAL . 9.1 mm -71.45 -25.28 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.534 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.415 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.3 t 63.98 112.49 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.62 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.965 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.748 0.309 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.26 162.65 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.539 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -69.84 88.8 0.54 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.594 2.196 . . . . 0.0 112.072 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' A' ' 129' ' ' ILE . 4.9 tt0 -55.75 -19.96 13.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.627 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.468 HG22 ' H ' ' A' ' 130' ' ' ASN . 0.2 OUTLIER -56.3 -160.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.65 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.468 ' H ' HG22 ' A' ' 129' ' ' ILE . 4.2 m-20 -68.33 -19.93 64.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.544 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.86 -19.87 60.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.661 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.06 -28.71 69.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.633 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.08 -30.01 48.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 2.3 m -60.99 -23.22 65.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.598 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 28.2 m -48.13 129.99 15.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.768 HG23 ' H ' ' A' ' 145' ' ' ASP . 0.5 OUTLIER -145.87 -99.35 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.678 179.942 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.768 ' H ' HG23 ' A' ' 144' ' ' THR . 97.9 m-20 -138.05 67.16 48.0 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.582 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -47.82 138.92 20.0 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.86 2.373 . . . . 0.0 112.081 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.7 m -66.27 147.3 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.601 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.1 -23.14 63.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.541 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.428 ' O ' HG22 ' A' ' 153' ' ' VAL . 0.3 OUTLIER -55.84 -21.48 20.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.547 179.894 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.96 -31.16 71.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.632 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.554 HD22 ' N ' ' A' ' 151' ' ' LEU . 3.8 mm? -69.93 -29.34 66.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.458 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 22.5 mt -71.4 -51.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.548 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 149' ' ' SER . 13.1 m -91.27 19.26 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.518 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.941 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.701 0.286 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 43.4 60.7 10.79 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.557 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.98 -168.62 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.711 2.274 . . . . 0.0 112.139 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.425 ' O ' ' N ' ' A' ' 130' ' ' ASN . 3.4 mt-30 -81.02 -62.21 1.73 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.502 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -68.18 66.09 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.593 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.425 ' N ' ' O ' ' A' ' 128' ' ' GLN . 0.1 OUTLIER -68.22 -22.4 64.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.544 -179.943 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -60.42 3.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.579 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt -62.14 -19.92 63.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.637 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 144' ' ' THR . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm -64.08 -62.67 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 3.1 m -60.98 -69.96 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.572 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 t -172.3 58.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.529 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 139' ' ' GLY . 0.2 OUTLIER 56.83 164.23 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.57 -179.996 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -76.21 161.07 76.45 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.433 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.482 ' HG2' HD23 ' A' ' 148' ' ' LEU . 38.0 Cg_endo -69.09 174.75 8.47 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.483 2.122 . . . . 0.0 112.143 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.631 ' O ' HG23 ' A' ' 147' ' ' VAL . 31.1 m -98.14 67.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.482 HD23 ' HG2' ' A' ' 146' ' ' PRO . 2.3 mm? -69.2 -33.48 73.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.411 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.4 ' O ' ' N ' ' A' ' 153' ' ' VAL . 14.2 p -55.91 -20.53 16.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.535 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.07 -32.05 73.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 151' ' ' LEU . 9.5 mp -69.78 -62.21 1.47 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.558 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.435 ' C ' HG23 ' A' ' 153' ' ' VAL . 12.0 tt -71.37 -20.38 21.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.511 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.435 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.3 t 64.83 141.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.624 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.671 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.955 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.6 tp . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.798 0.333 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 16.6 t80 63.83 60.29 1.75 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.62 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.7 144.79 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.693 2.262 . . . . 0.0 112.064 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.405 ' O ' ' N ' ' A' ' 130' ' ' ASN . 38.1 tt0 -81.79 -59.38 2.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.567 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.1 pt -66.21 72.81 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.575 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.405 ' N ' ' O ' ' A' ' 128' ' ' GLN . 24.5 t-20 -68.28 -23.85 64.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.507 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -60.88 -22.37 64.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.15 -57.22 12.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.6 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt -64.05 -26.39 40.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.2 m -61.14 -38.94 88.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 27.0 t -138.07 125.51 21.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.597 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -167.13 17.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.73 60.3 4.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.635 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.68 107.48 2.41 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.738 2.292 . . . . 0.0 112.117 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.63 13.38 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.528 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.1 mt -69.07 -34.5 75.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.587 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 6.2 m -55.78 -33.65 64.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.591 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.98 -20.25 66.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.569 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.86 -51.13 35.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.629 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.455 ' O ' ' C ' ' A' ' 153' ' ' VAL . 97.5 mt -71.43 -38.89 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.555 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.68 HG13 ' O ' ' A' ' 153' ' ' VAL . 9.3 p 22.32 51.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 124.06 0.85 . . . . 0.0 111.994 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.729 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.942 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.1 mt . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.838 0.352 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -147.78 67.33 10.22 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.491 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -47.87 107.77 0.15 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.907 2.405 . . . . 0.0 112.082 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -78.74 -20.35 50.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.577 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.78 141.66 17.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.583 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -68.37 -20.18 64.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.555 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.95 -68.46 0.31 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.557 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp -62.14 -25.94 68.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.1 -44.02 97.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.426 ' O ' ' CB ' ' A' ' 143' ' ' SER . 16.1 m -60.95 -27.46 68.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.608 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 75.44 139.36 0.06 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.569 -179.992 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.4 p -141.39 -20.24 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.603 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.0 162.64 51.32 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.466 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.76 169.73 18.23 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.587 2.191 . . . . 0.0 112.058 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.6 HG13 ' O ' ' A' ' 147' ' ' VAL . 12.5 p -95.53 115.38 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.559 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.442 ' N ' HD12 ' A' ' 148' ' ' LEU . 10.8 mp -69.07 -20.48 64.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.603 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 p -55.84 -22.16 23.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.59 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.08 -35.92 81.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.56 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 29.0 mt -69.8 -35.99 75.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.453 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.8 mt -71.36 -50.77 38.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.566 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.72 133.62 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.924 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.873 0.368 . . . . 0.0 110.543 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 41.57 62.24 7.3 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -75.76 102.2 1.57 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.791 2.327 . . . . 0.0 112.194 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 14.0 tt0 -82.01 -68.9 0.66 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 4.2 tt -83.75 -21.43 8.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.583 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.413 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.3 t30 -68.26 -20.56 64.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.596 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -60.99 -57.54 12.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt -62.22 -37.4 85.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.553 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 138' ' ' ALA . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.436 ' HB2' ' O ' ' A' ' 134' ' ' SER . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt -64.25 -56.21 17.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 143' ' ' SER . 20.9 p -61.01 -69.36 0.24 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.611 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.438 ' OG ' ' N ' ' A' ' 144' ' ' THR . 1.2 t 166.46 172.04 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.567 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.438 ' N ' ' OG ' ' A' ' 143' ' ' SER . 4.7 t -165.0 42.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.574 ' N ' ' CD ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -92.12 -43.33 0.36 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.051 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 145' ' ' ASP . 58.0 Cg_endo -86.66 -87.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.796 2.331 . . . . 0.0 112.223 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.756 HG13 ' H ' ' A' ' 148' ' ' LEU . 10.7 p -168.1 -120.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.45 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.756 ' H ' HG13 ' A' ' 147' ' ' VAL . 1.9 pp -68.58 -19.87 64.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.579 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.9 t -55.1 -49.3 72.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.503 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.3 -22.85 66.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.494 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.87 -25.35 63.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.607 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.8 mt -71.37 -64.1 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.606 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.645 HG22 ' O ' ' A' ' 153' ' ' VAL . 7.9 p -172.97 58.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.597 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.963 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.825 0.345 . . . . 0.0 110.469 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 57.4 65.85 3.33 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.599 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -46.1 157.4 0.4 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.831 2.354 . . . . 0.0 112.161 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.43 ' O ' ' O ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -84.95 -19.89 31.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.729 HG23 ' H ' ' A' ' 131' ' ' PHE . 0.6 OUTLIER -60.14 -145.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.233 -179.88 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.718 ' N ' HG23 ' A' ' 129' ' ' ILE . 3.3 t30 -68.71 -26.29 65.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.753 0.311 . . . . 0.0 110.547 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.729 ' H ' HG23 ' A' ' 129' ' ' ILE . 0.2 OUTLIER -60.83 -19.8 60.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.531 179.974 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 1.026 HD13 ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -61.78 -18.58 60.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.251 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 1.026 ' N ' HD13 ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.696 ' O ' HG22 ' A' ' 137' ' ' ILE . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.696 HG22 ' O ' ' A' ' 134' ' ' SER . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.14 -29.84 48.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 99.0 m -61.09 -20.19 62.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 p -41.92 158.16 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.584 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 144' ' ' THR . 0.1 OUTLIER -46.04 112.86 0.53 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.571 179.939 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.446 ' H ' ' HD2' ' A' ' 146' ' ' PRO . 0.1 OUTLIER 178.72 -50.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.896 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.446 ' HD2' ' H ' ' A' ' 145' ' ' ASP . 73.1 Cg_endo -83.0 176.1 7.91 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 122.28 1.987 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 147' ' ' VAL . 31.1 m -42.56 119.6 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.604 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.07 -19.93 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.526 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.78 -24.23 34.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.57 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.16 -24.03 66.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.615 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.86 -32.42 70.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.469 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 87.6 mt -71.43 -68.54 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.523 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.9 t -55.14 115.64 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.564 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.682 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.473 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 2.8 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.744 0.307 . . . . 0.0 110.487 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' A' ' 125' ' ' LEU . 91.1 m-85 -156.24 60.52 2.35 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.638 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.83 179.0 6.09 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.714 2.276 . . . . 0.0 112.143 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -51.61 -69.99 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.6 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.649 HG23 ' O ' ' A' ' 129' ' ' ILE . 4.6 tt -83.01 81.16 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.559 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.36 -20.04 64.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.497 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -61.03 -65.68 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.61 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt -62.14 -56.03 22.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.577 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.501 ' N ' ' OG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.481 ' O ' HG22 ' A' ' 142' ' ' THR . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.556 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.08 -29.18 46.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' THR . . . . . 0.481 HG22 ' O ' ' A' ' 139' ' ' GLY . 2.4 t -60.94 -26.88 67.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.605 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' SER . . . . . 0.403 ' O ' ' O ' ' A' ' 144' ' ' THR . 0.7 OUTLIER -99.36 -162.1 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.598 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.403 ' O ' ' O ' ' A' ' 143' ' ' SER . 16.3 p 55.17 106.98 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.477 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.449 ' CB ' ' CD ' ' A' ' 146' ' ' PRO . 0.9 OUTLIER -175.27 -64.73 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.937 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 145' ' ' ASP . 16.8 Cg_endo -58.48 170.11 2.67 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.168 1.912 . . . . 0.0 112.034 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 147' ' ' VAL . 7.2 p -90.83 5.01 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.572 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 tp -69.19 -39.78 78.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.429 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 93.2 p -55.7 -44.83 77.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.546 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -27.06 67.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.501 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.496 ' O ' HD23 ' A' ' 151' ' ' LEU . 1.1 tt -69.91 -55.34 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.598 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.42 -20.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.553 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.59 HG12 ' H ' ' A' ' 154' ' ' GLY . 2.6 t 63.31 -135.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.562 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.59 ' H ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.81 0.338 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.505 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 178.72 -47.15 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.76 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.505 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 32.8 Cg_exo -56.68 -149.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.23 1.953 . . . . 0.0 112.117 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -62.78 -19.8 64.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 46.8 mt -50.03 -28.98 4.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.554 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -68.23 -46.28 70.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.479 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -61.03 -21.08 63.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.452 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.12 -31.82 72.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.457 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.796 HG22 ' O ' ' A' ' 138' ' ' ALA . 15.9 tt -64.07 -27.08 41.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.0 p -61.02 -20.11 62.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.58 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.7 t -42.93 -91.6 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.578 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 27.6 p -141.34 -108.91 0.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.523 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 30.8 m-20 -155.5 60.11 2.41 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' O ' ' N ' ' A' ' 148' ' ' LEU . 55.3 Cg_endo -73.56 -167.54 0.38 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.715 2.277 . . . . 0.0 112.055 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 147' ' ' VAL . 7.5 p -45.59 94.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.532 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.448 ' N ' ' O ' ' A' ' 146' ' ' PRO . 1.0 OUTLIER -68.99 -20.12 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.564 -179.968 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.87 -20.75 16.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.523 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -33.83 76.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.584 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.82 -27.06 64.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.561 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 1.3 mm -71.55 -43.68 71.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.427 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.514 ' O ' HG12 ' A' ' 153' ' ' VAL . 97.2 t -62.0 -8.46 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.579 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.696 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.997 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 9.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.79 0.329 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.439 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.1 p90 -152.87 67.26 6.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.589 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.8 133.66 22.37 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 122.816 2.344 . . . . 0.0 112.076 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -79.26 -51.36 9.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 129' ' ' ILE . 16.8 tt -51.64 101.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.519 179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -68.37 -19.91 64.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.626 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -60.82 -69.91 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.627 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.1 -31.64 72.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.569 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 137' ' ' ILE . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.502 HG22 ' O ' ' A' ' 134' ' ' SER . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -63.96 -32.59 57.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 7.7 m -61.16 -31.88 71.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.507 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 1.3 t 172.42 132.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.561 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 145' ' ' ASP . 0.9 OUTLIER -87.78 102.66 14.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.52 -179.964 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 144' ' ' THR . 0.8 OUTLIER -30.46 95.57 0.08 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 O-C-N 123.768 0.668 . . . . 0.0 111.514 -179.883 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -54.52 119.02 5.72 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.11 1.874 . . . . 0.0 111.863 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.9 t -87.2 98.81 7.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mp -69.34 -29.07 66.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.581 179.919 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.86 -29.83 60.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.634 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.95 -40.74 91.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.571 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.78 -42.85 73.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.566 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.1 mt -71.45 -58.1 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.553 179.981 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 36.8 t -101.7 136.11 35.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.543 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.98 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.496 ' CG ' ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.793 0.33 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.496 ' H ' ' CG ' ' A' ' 125' ' ' LEU . 71.5 m-85 -138.8 60.74 19.82 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.649 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.432 ' O ' ' N ' ' A' ' 129' ' ' ILE . 55.9 Cg_endo -74.09 -168.05 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.683 2.256 . . . . 0.0 112.086 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.519 ' H ' ' CD ' ' A' ' 128' ' ' GLN . 7.5 mp0 -41.98 -25.45 0.06 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.556 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.536 HG22 ' HB2' ' A' ' 132' ' ' LEU . 18.7 mt -74.52 40.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.553 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.438 ' H ' ' C ' ' A' ' 128' ' ' GLN . 0.5 OUTLIER -68.31 -20.2 64.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.546 179.986 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.88 -33.93 73.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.562 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.536 ' HB2' HG22 ' A' ' 129' ' ' ILE . 1.4 mt -62.2 -42.1 98.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.486 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -22.76 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 70.5 p -60.98 -23.02 65.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.585 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.8 t -73.36 52.98 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.511 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.14 -47.3 5.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.588 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -145.0 67.12 13.27 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.532 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.467 ' C ' ' H ' ' A' ' 148' ' ' LEU . 52.0 Cg_exo -47.64 179.97 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.809 2.34 . . . . 0.0 112.199 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.433 ' H ' HG23 ' A' ' 147' ' ' VAL . 0.2 OUTLIER -61.99 -0.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.514 -179.997 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.467 ' H ' ' C ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -69.04 -49.63 55.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.423 179.997 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.95 -19.98 14.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.629 179.897 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.475 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -65.95 -25.0 66.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.655 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.22 -57.26 5.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.505 ' C ' HG23 ' A' ' 153' ' ' VAL . 5.7 mt -71.46 -65.6 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.623 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.1 t 66.3 153.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.603 -179.92 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.982 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.805 0.336 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 68.4 t80 44.63 60.74 12.28 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.617 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.11 131.77 15.84 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.674 2.249 . . . . 0.0 112.055 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -63.17 -43.43 98.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.533 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.2 mt -55.33 99.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.562 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -68.34 -22.86 64.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -60.91 -31.68 71.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.655 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.06 -26.0 68.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.57 179.925 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' ALA . 1.2 tp -64.1 -23.41 33.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 72.5 m -61.03 -66.84 0.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.594 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.0 m 42.75 77.07 0.07 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.589 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -138.31 -30.49 0.78 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.573 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 147' ' ' VAL . 48.1 t0 -145.45 60.53 6.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.567 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.85 20.16 0.39 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.753 2.302 . . . . 0.0 112.174 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.705 ' O ' HG12 ' A' ' 147' ' ' VAL . 61.2 t -77.08 48.69 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.606 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 3.1 mt -69.03 -20.38 64.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.564 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.93 -35.89 67.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.597 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.0 -20.17 66.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.59 179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 151' ' ' LEU . . . . . 0.471 ' O ' HD23 ' A' ' 151' ' ' LEU . 1.2 tt -69.74 -57.87 4.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.55 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.7 mt -71.44 -39.21 70.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.511 -179.909 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.44 142.57 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.628 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.978 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.769 0.319 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.483 ' H ' HD23 ' A' ' 125' ' ' LEU . 22.7 t80 -163.98 62.79 1.08 Allowed Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.623 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.7 -165.32 0.29 Allowed 'Trans proline' 0 C--N 1.306 -1.701 0 C-N-CA 122.691 2.26 . . . . 0.0 112.2 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -82.48 -48.77 10.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.782 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.424 ' C ' HD12 ' A' ' 129' ' ' ILE . 1.0 OUTLIER -85.16 32.2 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.095 0.474 . . . . 0.0 110.59 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -68.15 -25.88 65.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -60.97 -50.46 73.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.615 179.919 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp -62.05 -27.26 68.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.926 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt -64.08 -20.91 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.4 m -60.92 -66.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.7 p -87.18 139.55 30.45 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.525 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 65.89 159.77 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.494 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -150.59 60.54 4.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.653 -179.917 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.94 148.65 40.83 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.795 2.33 . . . . 0.0 112.045 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.1 m -99.73 -18.32 6.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.61 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.11 -63.66 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.597 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.487 ' O ' HG22 ' A' ' 152' ' ' ILE . 75.3 m -55.93 -29.87 60.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.934 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.06 -20.03 66.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.555 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.8 tp -69.81 -19.96 63.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.493 -179.929 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 152' ' ' ILE . . . . . 0.487 HG22 ' O ' ' A' ' 149' ' ' SER . 1.9 tp -71.42 -20.91 21.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.521 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.4 p -43.79 151.39 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.593 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 179.965 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.809 0.337 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.411 ' CD2' ' O ' ' A' ' 126' ' ' PHE . 75.1 t80 -162.3 67.23 1.97 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.79 111.32 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.806 2.337 . . . . 0.0 112.071 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -84.92 -20.08 31.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.52 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -56.41 137.57 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -68.35 -20.06 64.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.59 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -60.86 -65.72 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.09 -22.35 65.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.556 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt -64.12 -42.23 94.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 19.0 p -61.01 -22.5 64.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.577 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.5 t 60.99 78.24 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.7 t -172.23 150.33 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.503 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 43.23 67.25 3.81 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.593 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -47.76 137.67 21.02 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.773 2.315 . . . . 0.0 112.123 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 148' ' ' LEU . 63.3 t -77.01 154.77 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.606 179.96 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.465 ' N ' HD12 ' A' ' 148' ' ' LEU . 10.8 mp -69.07 -46.17 68.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.59 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 149' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 147' ' ' VAL . 0.6 OUTLIER -55.94 -43.84 77.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.548 179.959 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -22.73 66.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.542 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.0 tp -69.87 -22.6 63.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.528 -179.972 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 31.7 mt -71.47 -64.51 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.574 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -138.09 145.28 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.569 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.99 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.741 0.305 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.809 0.338 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.57 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 138' ' ' ALA . 11.4 tt . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.839 0.352 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.853 0.359 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.421 ' N ' HD12 ' A' ' 135' ' ' LEU . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.84 0.352 . . . . 0.0 110.504 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.73 HD23 ' H ' ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 134' ' ' SER . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.756 0.312 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.773 0.321 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 137' ' ' ILE . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.497 ' O ' HG22 ' A' ' 137' ' ' ILE . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.497 HG22 ' O ' ' A' ' 134' ' ' SER . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.506 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.506 HG22 ' O ' ' A' ' 138' ' ' ALA . 2.0 tp . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.745 0.307 . . . . 0.0 110.53 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.625 HG23 ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.625 ' N ' HG23 ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.786 0.327 . . . . 0.0 110.386 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.926 0.393 . . . . 0.0 110.632 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.505 HG22 ' O ' ' A' ' 134' ' ' SER . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.852 0.358 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 134' ' ' SER . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.798 0.332 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.739 0.304 . . . . 0.0 110.637 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.837 0.351 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.819 0.342 . . . . 0.0 110.634 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.804 0.335 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 138' ' ' ALA . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.436 ' HB2' ' O ' ' A' ' 134' ' ' SER . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 1.026 HD13 ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.807 0.337 . . . . 0.0 110.251 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 1.026 ' N ' HD13 ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.696 ' O ' HG22 ' A' ' 137' ' ' ILE . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.696 HG22 ' O ' ' A' ' 134' ' ' SER . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.81 0.338 . . . . 0.0 110.577 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.501 ' N ' ' OG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.556 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.859 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.796 HG22 ' O ' ' A' ' 138' ' ' ALA . 15.9 tt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.747 0.308 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 137' ' ' ILE . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.502 HG22 ' O ' ' A' ' 134' ' ' SER . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 CA--C 1.526 0.056 0 CA-C-O 120.724 0.297 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.749 0.309 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' ALA . 1.2 tp . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.362 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt . . . . . 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.78 0.324 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.549 HD22 ' N ' ' A' ' 125' ' ' LEU . 3.8 mm? . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 0.0 OUTLIER -95.62 162.61 23.74 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.396 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -69.78 173.36 11.1 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.557 2.171 . . . . 0.0 112.021 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.29 -24.09 37.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.58 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -85.01 19.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.556 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -68.24 -41.77 80.69 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.573 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -60.92 -58.18 9.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.3 mp -62.28 -34.44 76.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.56 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -65.02 -45.25 92.83 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.8 p -66.89 -20.18 65.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.858 0.361 . . . . 0.0 110.612 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.12 -43.78 86.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.436 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -64.34 -44.71 90.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.482 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 13.6 mt -67.97 -51.0 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.446 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -29.4 60.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.609 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.02 -42.77 54.95 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.881 -0.887 . . . . 0.0 110.881 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.4 m -65.8 -41.89 91.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.2 mt -64.14 -39.27 84.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.525 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 144' ' ' THR . 89.6 m -60.87 -64.51 0.93 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.625 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.405 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.3 OUTLIER 74.36 -36.79 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.583 -179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.473 ' H ' ' C ' ' A' ' 142' ' ' THR . 67.9 p -97.59 -107.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.579 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.471 ' N ' ' OG1' ' A' ' 144' ' ' THR . 0.0 OUTLIER -156.82 163.17 25.95 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.461 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -38.42 160.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.642 2.228 . . . . 0.0 112.209 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.48 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.2 OUTLIER -71.22 -19.43 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.584 179.914 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.9 mp -69.06 -38.25 78.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.598 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -55.9 -33.11 64.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.537 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.05 -30.91 71.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.51 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.88 -42.4 73.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.555 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 153' ' ' VAL . 6.8 mt -71.35 -31.42 43.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.617 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 152' ' ' ILE . 18.3 t 57.59 155.71 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.587 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.405 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.649 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 126' ' ' PHE . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.072 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.421 ' C ' ' O ' ' A' ' 125' ' ' LEU . 1.9 m-85 -32.92 98.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.343 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.274 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -83.75 162.71 14.22 Favored 'Trans proline' 0 N--CA 1.487 1.138 0 C-N-CA 122.207 1.938 . . . . 0.0 112.144 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -69.98 -53.25 18.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.604 ' O ' HG23 ' A' ' 129' ' ' ILE . 15.6 tt -61.57 113.32 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.539 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -68.37 -20.23 64.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.602 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -61.02 -64.67 0.88 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.584 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.24 -31.03 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.583 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.26 -23.1 32.27 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -66.93 -37.99 85.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.843 0.354 . . . . 0.0 110.502 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.2 mp -66.23 -28.58 68.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.499 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mt -64.41 -31.84 73.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.529 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.1 mm -67.81 -55.81 15.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.517 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.57 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.03 -21.33 20.95 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.645 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -53.05 -20.5 8.81 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . 0.451 ' O ' ' SG ' ' A' ' 140' ' ' CYS . 0.1 OUTLIER -65.87 -19.88 66.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.557 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 138' ' ' ALA . 11.4 tt -64.18 -33.38 62.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.535 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.403 ' O ' ' O ' ' A' ' 143' ' ' SER . 1.2 m -60.93 -20.76 62.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.603 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.403 ' O ' ' O ' ' A' ' 142' ' ' THR . 6.5 t -61.06 -137.05 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.549 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 59.1 114.81 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.593 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.07 162.61 51.37 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.541 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.77 -84.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.308 -1.576 0 C-N-CA 122.503 2.135 . . . . 0.0 112.106 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 147' ' ' VAL . 84.1 t -148.08 2.07 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.585 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 5.9 mt -69.11 -41.79 76.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 36.7 t -55.87 -27.7 53.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.621 ' O ' HG13 ' A' ' 153' ' ' VAL . . . -65.97 -37.16 85.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.613 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 22.9 mt -69.84 -34.3 73.44 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.608 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.419 ' O ' ' C ' ' A' ' 153' ' ' VAL . 72.3 mt -71.53 -50.46 39.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.604 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.621 HG13 ' O ' ' A' ' 150' ' ' ALA . 1.2 m 31.54 86.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.401 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.681 0.277 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.486 ' N ' ' CD1' ' A' ' 126' ' ' PHE . 2.2 p90 -135.21 69.53 69.32 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.496 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -80.33 -178.84 4.75 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.777 2.318 . . . . 0.0 112.225 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -74.28 -39.6 62.84 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 95.1 mt -41.68 -33.52 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.536 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -68.28 -45.54 72.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -61.07 -51.1 70.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.548 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -62.16 -31.68 72.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.48 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -76.99 -37.16 33.73 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 24.4 m -66.93 -25.89 66.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.748 0.308 . . . . 0.0 110.53 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 mp -66.08 -30.58 71.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.602 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -43.94 93.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.443 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 4.5 mt -67.86 -58.41 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.577 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -36.98 68.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.601 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -54.8 -20.02 16.9 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.81 -63.53 1.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.735 0.303 . . . . 0.0 110.457 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.3 pt -64.15 -22.34 30.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.597 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 23.8 m -61.0 -37.99 84.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.593 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 3.8 t 47.5 -143.66 0.37 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.556 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 11.3 p -47.79 132.08 14.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.545 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -92.99 162.58 28.25 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.479 ' C ' ' H ' ' A' ' 148' ' ' LEU . 39.8 Cg_endo -69.71 -166.87 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.575 2.183 . . . . 0.0 112.08 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.3 m -54.99 -6.87 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.563 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.479 ' H ' ' C ' ' A' ' 146' ' ' PRO . 3.5 tp -69.1 -19.91 64.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.525 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -55.96 -22.23 25.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.588 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.423 ' O ' ' O ' ' A' ' 153' ' ' VAL . . . -66.02 -20.16 66.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.553 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.467 HD23 ' O ' ' A' ' 151' ' ' LEU . 1.2 tt -69.78 -57.81 4.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.602 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.593 HG23 HG23 ' A' ' 153' ' ' VAL . 6.4 tt -71.42 -30.35 39.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.492 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.593 HG23 HG23 ' A' ' 152' ' ' ILE . 59.6 t -94.31 133.59 34.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.531 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.624 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.07 0 CA-C-O 120.843 0.354 . . . . 0.0 110.479 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 21.5 t80 60.4 60.5 3.76 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.672 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.85 -172.02 1.01 Allowed 'Trans proline' 0 C--N 1.306 -1.666 0 C-N-CA 122.676 2.251 . . . . 0.0 112.177 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -76.41 -51.52 11.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.524 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.4 mt -76.83 110.95 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.573 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.484 ' OD1' ' N ' ' A' ' 131' ' ' PHE . 25.7 p30 -68.25 -27.31 66.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.602 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.484 ' N ' ' OD1' ' A' ' 130' ' ' ASN . 41.0 m-85 -61.01 -53.05 61.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.588 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.4 mt -62.05 -34.64 76.64 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.604 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.17 -23.96 8.79 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 66.4 m -66.97 -42.38 85.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.578 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.421 ' N ' HD12 ' A' ' 135' ' ' LEU . 10.7 mp -66.02 -20.49 66.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.67 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.3 tp -64.42 -37.48 87.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.562 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 15.5 mt -67.92 -29.93 46.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.497 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.94 -20.11 14.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.568 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -66.73 -38.42 93.11 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -65.85 -37.76 87.07 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.805 0.336 . . . . 0.0 110.526 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.05 -40.92 90.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.571 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -60.86 -65.23 0.72 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.669 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.442 ' OG ' ' N ' ' A' ' 144' ' ' THR . 95.3 p 42.6 -112.38 0.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.555 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.442 ' N ' ' OG ' ' A' ' 143' ' ' SER . 9.2 t -92.38 164.42 13.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.561 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 41.85 73.94 0.83 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.446 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' C ' ' A' ' 147' ' ' VAL . 36.4 Cg_exo -56.97 -66.11 0.09 OUTLIER 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.776 2.317 . . . . 0.0 112.077 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.424 ' C ' ' O ' ' A' ' 146' ' ' PRO . 31.3 m 33.12 39.89 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.204 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.0 -22.14 64.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.491 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.1 p -56.18 -25.89 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.544 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.91 -46.92 76.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.573 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 13.4 mt -69.88 -34.08 73.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.537 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.4 ' O ' ' O ' ' A' ' 153' ' ' VAL . 93.1 mt -71.41 -19.97 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.582 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 152' ' ' ILE . 1.5 t 56.54 162.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.552 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.966 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 13.6 mt . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.738 0.304 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -138.71 162.68 51.58 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.441 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.11 156.87 61.42 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.592 2.195 . . . . 0.0 112.114 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -84.91 -55.01 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.609 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.548 HD13 ' H ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -76.51 111.87 13.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.449 179.941 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.32 -32.03 71.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.708 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -60.9 -67.21 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.509 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.51 ' O ' ' N ' ' A' ' 134' ' ' SER . 3.6 mp -62.28 -23.38 66.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.504 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.03 -19.79 0.05 OUTLIER Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.51 ' N ' ' O ' ' A' ' 132' ' ' LEU . 3.1 t -66.42 -70.27 0.25 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.714 0.292 . . . . 0.0 110.727 -179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.73 HD23 ' H ' ' A' ' 135' ' ' LEU . 0.1 OUTLIER -66.68 -25.06 66.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.697 -179.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.42 -20.16 65.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.524 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 134' ' ' SER . 1.7 tp -67.86 -20.51 26.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.636 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.97 -19.93 14.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.56 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -80.77 -23.71 59.45 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 75.6 m -65.75 -20.02 66.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.614 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 83.1 mt -64.15 -23.51 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.514 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.455 ' O ' ' CB ' ' A' ' 143' ' ' SER . 40.6 p -60.91 -21.71 63.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.619 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 78.4 130.89 0.05 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.49 179.933 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.1 150.57 37.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.619 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.407 ' O ' ' OD2' ' A' ' 145' ' ' ASP . 6.8 p-10 41.3 67.16 3.2 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.607 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.84 175.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.736 2.29 . . . . 0.0 112.152 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 53.1 t -100.85 -32.34 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.623 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mt -69.13 -63.68 1.02 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -24.6 38.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.19 -25.86 67.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.53 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.82 -34.44 73.69 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.578 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 9.2 mm -71.41 -21.61 21.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.575 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.56 HG12 ' N ' ' A' ' 154' ' ' GLY . 69.0 t 53.33 -91.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.628 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.56 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.606 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 39.0 tp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.783 0.325 . . . . 0.0 110.408 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.515 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 83.4 t80 -171.4 60.81 0.32 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -74.14 149.63 41.37 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.76 2.307 . . . . 0.0 112.09 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 38.4 mt-30 -84.27 -59.27 2.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.558 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 81.7 mt -56.5 105.59 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.56 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -68.41 -33.18 73.78 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.532 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -61.06 -20.7 62.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.554 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.9 tt -62.17 -33.15 73.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.528 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.02 -30.65 0.73 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.3 m -66.95 -53.9 27.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.765 0.317 . . . . 0.0 110.514 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.2 mp -66.14 -24.88 66.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.581 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.42 -23.47 67.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 94.4 mt -67.89 -59.43 3.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.94 18.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.532 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -67.67 -20.63 72.27 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . 0.513 ' SG ' ' N ' ' A' ' 141' ' ' ILE . 1.9 p -65.67 -36.46 83.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.546 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.513 ' N ' ' SG ' ' A' ' 140' ' ' CYS . 6.3 mt -64.08 -29.59 47.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.586 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 61.8 m -61.02 -27.95 68.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.559 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 69.0 m -44.67 157.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.542 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.46 ' OG1' ' N ' ' A' ' 145' ' ' ASP . 59.8 p -139.52 -106.38 0.16 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.59 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.46 ' N ' ' OG1' ' A' ' 144' ' ' THR . 0.0 OUTLIER -87.1 163.15 41.38 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.493 -179.982 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.418 ' O ' ' O ' ' A' ' 145' ' ' ASP . 83.9 Cg_exo -38.38 162.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.307 -1.612 0 C-N-CA 122.699 2.266 . . . . 0.0 112.191 179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 4.5 p -137.75 151.99 26.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.11 -27.64 65.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.436 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -55.83 -20.16 14.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.454 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -66.1 -19.93 66.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.546 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 4.6 tp -69.81 -60.24 2.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.546 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.476 ' C ' HG23 ' A' ' 153' ' ' VAL . 74.6 mt -71.51 -65.42 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.568 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.587 HG12 ' H ' ' A' ' 154' ' ' GLY . 2.2 t 65.41 -139.62 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.592 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.587 ' H ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 mm? . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.7 0.286 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.461 ' N ' ' CD1' ' A' ' 126' ' ' PHE . 2.9 p90 -134.96 69.31 70.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.602 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -80.2 174.52 11.32 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.872 2.381 . . . . 0.0 112.171 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.479 ' C ' ' H ' ' A' ' 130' ' ' ASN . 3.8 tp-100 -79.29 -36.51 39.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.547 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -64.97 3.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.575 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.479 ' H ' ' C ' ' A' ' 128' ' ' GLN . 54.4 t30 -68.27 -30.14 69.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.585 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -60.98 -45.0 96.55 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.604 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 8.6 mp -62.08 -20.25 63.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.574 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.49 -23.36 27.21 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -67.02 -45.68 76.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.691 0.281 . . . . 0.0 110.43 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.4 mt -66.51 -19.58 65.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.641 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.0 tp -63.28 -37.29 86.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.908 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 137' ' ' ILE . 0.5 OUTLIER -67.71 -24.39 30.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.848 0.356 . . . . 0.0 110.607 -179.886 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -55.93 -44.68 78.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.614 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -72.86 -30.77 63.08 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 1.4 t -65.76 -37.19 85.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.87 0.367 . . . . 0.0 110.585 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 62.6 mt -64.08 -40.61 89.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -28.4 68.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.597 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 144' ' ' THR . 0.2 OUTLIER -99.88 167.92 10.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.568 -179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.44 HG23 ' H ' ' A' ' 144' ' ' THR . 10.9 p -43.22 167.85 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.589 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -89.09 161.05 41.82 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.415 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.17 159.14 55.02 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.493 2.129 . . . . 0.0 112.072 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 47.3 t -96.43 95.57 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.512 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.07 -28.13 66.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.51 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 11.5 t -55.93 -20.45 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.535 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.685 ' O ' HG23 ' A' ' 153' ' ' VAL . . . -66.11 -33.63 76.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.588 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.87 -24.31 63.4 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.439 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 3.4 mm -71.32 -68.77 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.526 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.685 HG23 ' O ' ' A' ' 150' ' ' ALA . 45.7 t 50.99 93.8 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.616 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.527 0.81 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.795 0.331 . . . . 0.0 110.62 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 27.1 t80 59.84 67.22 1.82 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.608 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -47.87 175.14 0.02 OUTLIER 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.856 2.371 . . . . 0.0 112.073 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -68.75 -68.8 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.4 mm -84.33 135.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.452 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 27.0 m-20 -68.21 -42.93 79.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.626 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -61.09 -68.68 0.29 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.49 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 5.5 mp -62.06 -26.57 68.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.554 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -48.54 -43.49 28.27 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.497 ' O ' HG22 ' A' ' 137' ' ' ILE . 0.1 OUTLIER -66.92 -48.42 68.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.595 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.0 -26.74 67.68 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.548 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.6 mt -64.31 -20.05 65.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.568 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.497 HG22 ' O ' ' A' ' 134' ' ' SER . 1.5 tp -67.91 -22.97 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.565 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.506 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -22.24 25.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.518 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.56 -22.37 58.47 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.81 -20.8 66.38 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.772 0.32 . . . . 0.0 110.555 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.506 HG22 ' O ' ' A' ' 138' ' ' ALA . 2.0 tp -64.22 -35.73 74.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.531 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 82.6 p -60.96 -27.5 68.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.516 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.89 -49.64 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.516 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 55.0 p -82.45 162.89 21.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -99.17 161.29 25.24 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.446 179.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 145' ' ' ASP . 82.0 Cg_exo -38.45 163.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.673 2.249 . . . . 0.0 112.117 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.407 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.7 OUTLIER -49.91 171.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.18 -29.9 67.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.498 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 4.4 m -55.95 -39.0 71.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.646 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -20.42 66.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.714 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.4 tp -69.92 -40.04 75.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.558 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.42 -65.79 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.567 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.91 HG22 ' H ' ' A' ' 154' ' ' GLY . 9.7 p -94.62 -141.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.247 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.91 ' H ' HG22 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 1.4 mt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.851 0.358 . . . . 0.0 110.63 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 42.1 t80 53.5 60.86 11.4 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.581 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.04 124.48 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 C-N-CA 122.619 2.213 . . . . 0.0 112.099 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 129' ' ' ILE . 3.3 tt0 -85.14 -19.78 31.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.584 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.664 HG22 ' N ' ' A' ' 130' ' ' ASN . 2.7 mp -44.83 170.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.533 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.664 ' N ' HG22 ' A' ' 129' ' ' ILE . 4.5 p-10 -67.51 -19.7 65.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.875 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -59.68 -19.85 52.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.602 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.3 tt -61.96 -34.14 75.57 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.53 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -50.58 -24.88 8.12 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.93 -30.48 70.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 110.582 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.1 tp -66.08 -20.32 66.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.555 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.3 tp -64.38 -63.35 1.16 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.545 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.625 HG23 ' N ' ' A' ' 138' ' ' ALA . 17.9 tt -67.88 -48.58 74.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.561 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.625 ' N ' HG23 ' A' ' 137' ' ' ILE . . . -56.02 -25.0 42.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.571 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -47.8 -20.05 1.09 Allowed Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -65.74 -58.85 4.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.788 0.328 . . . . 0.0 110.577 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.12 -37.83 80.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.445 ' O ' ' CB ' ' A' ' 143' ' ' SER . 2.6 m -61.0 -24.06 65.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.58 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.445 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.7 OUTLIER 76.83 -57.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.556 -179.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 43.8 p -69.37 156.15 39.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.538 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 143' ' ' SER . 0.0 OUTLIER -154.88 163.2 25.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.453 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 145' ' ' ASP . 81.0 Cg_exo -38.53 163.34 0.02 OUTLIER 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.584 2.189 . . . . 0.0 112.3 179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 147' ' ' VAL . 0.3 OUTLIER -45.41 168.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 148' ' ' LEU . 9.8 mp -68.98 -20.11 64.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.638 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.91 -40.67 73.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.562 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -20.04 66.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.518 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 151' ' ' LEU . 1.2 tt -69.88 -58.7 3.56 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.565 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.404 ' O ' ' O ' ' A' ' 153' ' ' VAL . 69.1 mt -71.45 -23.77 23.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.601 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.629 HG12 ' N ' ' A' ' 154' ' ' GLY . 58.0 t 55.21 165.31 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.538 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.629 ' N ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.877 0.37 . . . . 0.0 110.619 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.496 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 179.48 -47.24 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.921 179.726 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 39.1 Cg_exo -57.68 169.13 2.65 Favored 'Trans proline' 0 N--CA 1.495 1.567 0 C-N-CA 122.141 1.894 . . . . 0.0 112.014 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -81.3 -39.97 24.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.465 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.6 mt -71.12 -17.57 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.469 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -20.76 64.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.475 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.421 ' CD1' ' C ' ' A' ' 131' ' ' PHE . 3.4 t80 -60.77 -25.21 66.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.587 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -62.27 -66.09 0.59 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.386 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.6 -33.59 62.85 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.5 t -66.75 -33.32 75.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 0.0 110.452 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 40.5 tp -66.0 -29.4 69.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.413 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.9 mp -64.34 -60.75 2.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.603 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.0 mt -67.93 -62.35 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.05 -21.69 23.2 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.566 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.55 -41.76 3.31 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 84.9 m -65.78 -53.69 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.761 0.315 . . . . 0.0 110.555 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.8 mt -64.11 -25.52 38.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.578 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 3.2 m -60.88 -31.44 70.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.584 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 12.0 t 53.11 -95.96 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.586 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 29.9 p -67.16 114.15 5.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' O ' ' O ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -81.95 161.49 60.49 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.891 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' A' ' 145' ' ' ASP . 80.5 Cg_exo -38.27 162.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.682 2.255 . . . . 0.0 112.214 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.41 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 36.8 t -99.8 -52.37 8.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.541 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mt -69.12 -55.35 10.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.588 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.97 -19.53 12.79 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.657 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 147' ' ' VAL . . . -65.24 -20.31 66.37 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.771 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.405 ' N ' HD12 ' A' ' 151' ' ' LEU . 9.2 mp -69.85 -48.99 56.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.644 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 21.9 pt -71.57 -30.12 37.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.599 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.9 t -47.65 142.37 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.523 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.638 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.996 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.882 0.372 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 48.62 67.23 4.71 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.563 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -47.71 176.15 0.02 OUTLIER 'Trans proline' 0 C--N 1.306 -1.708 0 C-N-CA 122.812 2.342 . . . . 0.0 112.131 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -78.15 -41.71 33.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.624 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -71.68 96.37 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.579 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -68.35 -29.71 68.5 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.561 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -60.97 -64.86 0.81 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.528 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.517 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.5 mp -62.04 -31.77 72.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.632 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.08 -21.49 0.05 OUTLIER Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 132' ' ' LEU . 20.3 m -66.97 -69.06 0.33 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.658 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.5 mt -66.17 -27.77 68.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.653 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.2 mt -64.27 -20.01 65.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.543 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.505 HG22 ' O ' ' A' ' 134' ' ' SER . 1.6 tp -67.59 -19.89 25.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.632 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -20.32 16.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.82 -23.17 64.78 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 9.3 t -65.68 -27.97 68.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.781 0.324 . . . . 0.0 110.557 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 11.5 mt -64.15 -53.33 44.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.556 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.42 ' O ' ' O ' ' A' ' 143' ' ' SER . 12.5 p -61.01 -67.03 0.44 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.59 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.42 ' O ' ' O ' ' A' ' 142' ' ' THR . 1.3 p 56.85 158.71 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.578 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 75.0 p -95.2 92.49 6.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.539 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -70.94 161.08 80.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.42 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -68.86 -169.74 0.3 Allowed 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.487 2.124 . . . . 0.0 112.046 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 2.2 t -137.17 -26.93 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.566 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.497 ' H ' HD23 ' A' ' 148' ' ' LEU . 0.2 OUTLIER -69.1 -34.81 75.68 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.544 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 t -55.95 -40.38 73.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.582 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -25.98 67.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.52 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -69.95 -44.82 68.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.369 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.1 mt -71.51 -57.39 7.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.579 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.1 t -142.44 120.49 7.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.547 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.739 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.95 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.772 0.32 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.552 ' N ' ' CD1' ' A' ' 126' ' ' PHE . 1.3 p90 -137.34 70.43 54.26 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.584 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -49.58 -175.43 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.755 0 C-N-CA 122.805 2.337 . . . . 0.0 112.052 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -75.67 -22.42 56.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.619 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 72.4 mt -43.32 102.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.534 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -68.37 -21.22 64.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.543 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -61.07 -29.22 69.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.604 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.1 tp -62.17 -21.69 65.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.586 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -42.94 -21.03 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' LEU . 11.1 t -66.92 -61.67 1.83 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.808 0.337 . . . . 0.0 110.597 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.1 mp -66.13 -24.77 66.74 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.561 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -64.37 -20.22 65.98 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.55 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 134' ' ' SER . 5.3 tt -67.92 -21.4 26.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.559 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.35 44.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.565 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -84.39 -26.17 40.65 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.0 t -65.75 -23.45 66.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.872 0.368 . . . . 0.0 110.608 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -24.92 36.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.523 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 80.9 p -60.96 -20.84 62.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.565 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 71.2 47.74 0.39 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.592 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.574 HG22 ' H ' ' A' ' 145' ' ' ASP . 5.9 m -84.66 -130.1 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.563 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.574 ' H ' HG22 ' A' ' 144' ' ' THR . 2.1 m-20 -154.08 67.34 5.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.579 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.402 ' O ' ' O ' ' A' ' 145' ' ' ASP . 52.3 Cg_exo -47.81 -178.23 0.0 OUTLIER 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.804 2.336 . . . . 0.0 112.077 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.647 ' O ' HG23 ' A' ' 147' ' ' VAL . 27.8 m -91.91 66.25 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.627 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 6.7 mt -69.05 -21.38 64.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.563 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 3.4 p -55.96 -21.18 19.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.575 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.04 -42.12 89.97 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.593 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.3 tp -69.83 -43.02 72.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' VAL . 9.1 mm -71.45 -25.28 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.534 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.415 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.3 t 63.98 112.49 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.62 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.965 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.748 0.309 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.26 162.65 0.15 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.539 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -69.84 88.8 0.54 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.594 2.196 . . . . 0.0 112.072 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' A' ' 129' ' ' ILE . 1.8 tt0 -55.75 -19.96 13.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.627 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.468 HG22 ' H ' ' A' ' 130' ' ' ASN . 0.2 OUTLIER -56.3 -160.66 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.65 179.947 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.468 ' H ' HG22 ' A' ' 129' ' ' ILE . 4.2 m-20 -68.33 -19.93 64.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.544 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -60.86 -19.87 60.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.661 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.06 -28.71 69.8 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.633 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -49.01 -27.42 6.72 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 11.1 p -66.97 -42.19 85.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.834 0.35 . . . . 0.0 110.587 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.8 mp -66.16 -21.22 66.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.541 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.43 -43.73 93.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.373 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 82.7 mt -67.83 -29.69 45.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.592 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.434 ' O ' ' N ' ' A' ' 140' ' ' CYS . . . -55.95 -22.46 26.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.597 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -44.45 -20.33 0.19 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . 0.434 ' N ' ' O ' ' A' ' 138' ' ' ALA . 19.0 p -65.9 -40.33 91.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.843 0.354 . . . . 0.0 110.532 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.08 -30.01 48.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.484 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 2.3 m -60.99 -23.22 65.21 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.598 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 28.2 m -48.13 129.99 15.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.526 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.768 HG23 ' H ' ' A' ' 145' ' ' ASP . 0.5 OUTLIER -145.87 -99.35 0.1 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.678 179.942 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.768 ' H ' HG23 ' A' ' 144' ' ' THR . 97.9 m-20 -138.05 67.16 48.0 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.582 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -47.82 138.92 20.0 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.86 2.373 . . . . 0.0 112.081 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 13.7 m -66.27 147.3 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.601 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.1 -23.14 63.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.541 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.428 ' O ' HG22 ' A' ' 153' ' ' VAL . 0.3 OUTLIER -55.84 -21.48 20.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.547 179.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.96 -31.16 71.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.632 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.554 ' N ' HD22 ' A' ' 151' ' ' LEU . 3.8 mm? -69.93 -29.34 66.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.458 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 22.5 mt -71.4 -51.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.548 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 149' ' ' SER . 13.1 m -91.27 19.26 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.518 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.661 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.941 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.701 0.286 . . . . 0.0 110.622 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 43.4 60.7 10.79 Favored Pre-proline 0 C--N 1.327 -0.386 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.557 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -73.98 -168.62 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.711 2.274 . . . . 0.0 112.139 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.425 ' O ' ' N ' ' A' ' 130' ' ' ASN . 3.4 mt-30 -81.02 -62.21 1.73 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.502 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -68.18 66.09 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.593 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.425 ' N ' ' O ' ' A' ' 128' ' ' GLN . 0.1 OUTLIER -68.22 -22.4 64.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.544 -179.943 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -60.42 3.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.579 180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.7 mt -62.14 -19.92 63.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.637 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.79 -35.1 1.41 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -66.96 -51.93 49.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.8 0.333 . . . . 0.0 110.576 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 6.1 mt -66.13 -20.37 66.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.487 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -64.31 -26.35 68.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.542 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 39.9 mt -67.94 -53.41 30.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.585 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.08 -19.99 15.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.653 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 144' ' ' THR . . . -79.84 -41.34 12.75 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -65.81 -25.96 67.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.769 0.319 . . . . 0.0 110.549 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 3.4 mm -64.08 -62.67 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.537 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 3.1 m -60.98 -69.96 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.572 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 t -172.3 58.02 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.529 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 139' ' ' GLY . 0.2 OUTLIER 56.83 164.23 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.57 -179.996 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -76.21 161.07 76.45 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.433 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.482 ' HG2' HD23 ' A' ' 148' ' ' LEU . 38.0 Cg_endo -69.09 174.75 8.47 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 122.483 2.122 . . . . 0.0 112.143 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.631 ' O ' HG23 ' A' ' 147' ' ' VAL . 31.1 m -98.14 67.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.578 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.482 HD23 ' HG2' ' A' ' 146' ' ' PRO . 2.3 mm? -69.2 -33.48 73.42 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.411 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.4 ' O ' ' N ' ' A' ' 153' ' ' VAL . 14.2 p -55.91 -20.53 16.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.535 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.07 -32.05 73.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.531 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.635 HD12 ' N ' ' A' ' 151' ' ' LEU . 9.5 mp -69.78 -62.21 1.47 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.558 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.435 ' C ' HG23 ' A' ' 153' ' ' VAL . 12.0 tt -71.37 -20.38 21.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.511 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.435 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.3 t 64.83 141.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.624 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.671 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.955 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.6 tp . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.798 0.333 . . . . 0.0 110.538 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 16.6 t80 63.83 60.29 1.75 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.62 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.7 144.79 35.89 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.693 2.262 . . . . 0.0 112.064 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.405 ' O ' ' N ' ' A' ' 130' ' ' ASN . 38.1 tt0 -81.79 -59.38 2.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.567 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 2.1 pt -66.21 72.81 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.575 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.405 ' N ' ' O ' ' A' ' 128' ' ' GLN . 24.5 t-20 -68.28 -23.85 64.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.507 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -60.88 -22.37 64.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 4.4 tp -62.15 -57.22 12.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.6 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -62.47 -30.4 76.29 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.92 -23.54 65.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.826 0.346 . . . . 0.0 110.54 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 44.1 tp -66.0 -46.97 76.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.337 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.42 -42.34 96.11 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.546 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 93.9 mt -68.02 -33.83 63.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -20.44 16.86 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.479 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.72 -20.84 75.85 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 37.7 t -65.76 -57.14 8.71 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.594 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.7 pt -64.05 -26.39 40.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.582 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.2 m -61.14 -38.94 88.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 27.0 t -138.07 125.51 21.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.597 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -167.13 17.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.536 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -149.73 60.3 4.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.635 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.68 107.48 2.41 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 C-N-CA 122.738 2.292 . . . . 0.0 112.117 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.63 13.38 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.528 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.1 mt -69.07 -34.5 75.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.587 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 6.2 m -55.78 -33.65 64.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.591 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.98 -20.25 66.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.569 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.5 tp -69.86 -51.13 35.98 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.629 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.455 ' O ' ' C ' ' A' ' 153' ' ' VAL . 97.5 mt -71.43 -38.89 70.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.555 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.68 ' O ' HG13 ' A' ' 153' ' ' VAL . 9.3 p 22.32 51.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 124.06 0.85 . . . . 0.0 111.994 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.729 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 179.942 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 5.1 mt . . . . . 0 C--O 1.23 0.056 0 CA-C-O 120.838 0.352 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -147.78 67.33 10.22 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.491 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -47.87 107.77 0.15 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.907 2.405 . . . . 0.0 112.082 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.1 mm-40 -78.74 -20.35 50.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.577 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -64.78 141.66 17.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.583 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -68.37 -20.18 64.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.555 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -60.95 -68.46 0.31 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.557 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.8 mp -62.14 -25.94 68.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.05 -20.78 76.62 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 38.4 m -66.94 -33.77 76.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.864 0.364 . . . . 0.0 110.592 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 7.7 mt -66.17 -20.11 66.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.554 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -64.32 -54.54 31.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.592 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 20.8 pt -67.98 -28.23 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.577 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.04 -25.25 44.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.557 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -76.95 -23.46 69.13 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 3.8 t -65.81 -33.6 76.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.756 0.312 . . . . 0.0 110.573 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.572 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.1 -44.02 97.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.61 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.426 ' O ' ' CB ' ' A' ' 143' ' ' SER . 16.1 m -60.95 -27.46 68.26 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.608 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 142' ' ' THR . 0.5 OUTLIER 75.44 139.36 0.06 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.569 -179.992 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 2.4 p -141.39 -20.24 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.603 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.0 162.64 51.32 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.466 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -69.76 169.73 18.23 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.587 2.191 . . . . 0.0 112.058 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.6 ' O ' HG13 ' A' ' 147' ' ' VAL . 12.5 p -95.53 115.38 34.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.559 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.442 ' N ' HD12 ' A' ' 148' ' ' LEU . 10.8 mp -69.07 -20.48 64.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.603 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.4 p -55.84 -22.16 23.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.59 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.08 -35.92 81.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.56 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 29.0 mt -69.8 -35.99 75.31 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.453 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 7.8 mt -71.36 -50.77 38.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.566 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.72 133.62 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.924 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.873 0.368 . . . . 0.0 110.543 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 41.57 62.24 7.3 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.629 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -75.76 102.2 1.57 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.791 2.327 . . . . 0.0 112.194 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 14.0 tt0 -82.01 -68.9 0.66 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 4.2 tt -83.75 -21.43 8.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.583 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.413 ' O ' ' N ' ' A' ' 134' ' ' SER . 2.3 t30 -68.26 -20.56 64.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.596 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -60.99 -57.54 12.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 mt -62.22 -37.4 85.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.553 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -74.03 -28.47 64.45 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 138' ' ' ALA . 4.5 m -66.91 -29.17 68.98 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.573 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 mp -66.19 -47.67 73.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.593 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.5 tp -64.31 -46.6 82.85 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.634 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 87.9 mt -67.87 -35.73 73.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.455 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.436 ' HB2' ' O ' ' A' ' 134' ' ' SER . . . -55.85 -42.99 76.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.632 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -57.86 -42.6 94.73 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.79 -46.03 80.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.813 0.34 . . . . 0.0 110.595 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 40.0 mt -64.25 -56.21 17.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.491 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 143' ' ' SER . 20.9 p -61.01 -69.36 0.24 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.611 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.438 ' OG ' ' N ' ' A' ' 144' ' ' THR . 1.2 t 166.46 172.04 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.567 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.438 ' N ' ' OG ' ' A' ' 143' ' ' SER . 4.7 t -165.0 42.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.614 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.574 ' N ' ' CD ' ' A' ' 146' ' ' PRO . 0.0 OUTLIER -92.12 -43.33 0.36 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.051 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.574 ' CD ' ' N ' ' A' ' 145' ' ' ASP . 58.0 Cg_endo -86.66 -87.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.796 2.331 . . . . 0.0 112.223 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.756 HG13 ' H ' ' A' ' 148' ' ' LEU . 10.7 p -168.1 -120.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.45 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.756 ' H ' HG13 ' A' ' 147' ' ' VAL . 1.9 pp -68.58 -19.87 64.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.579 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 1.9 t -55.1 -49.3 72.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.503 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.3 -22.85 66.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.494 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.1 tp -69.87 -25.35 63.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.607 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.8 mt -71.37 -64.1 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.606 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.645 ' O ' HG22 ' A' ' 153' ' ' VAL . 7.9 p -172.97 58.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.597 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.963 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.3 mm? . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.825 0.345 . . . . 0.0 110.469 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 57.4 65.85 3.33 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.599 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_exo -46.1 157.4 0.4 Allowed 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.831 2.354 . . . . 0.0 112.161 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.43 ' O ' ' O ' ' A' ' 129' ' ' ILE . 0.0 OUTLIER -84.95 -19.89 31.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 179.994 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.729 HG23 ' H ' ' A' ' 131' ' ' PHE . 0.6 OUTLIER -60.14 -145.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.233 -179.88 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.718 ' N ' HG23 ' A' ' 129' ' ' ILE . 3.3 t30 -68.71 -26.29 65.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.753 0.311 . . . . 0.0 110.547 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.729 ' H ' HG23 ' A' ' 129' ' ' ILE . 0.2 OUTLIER -60.83 -19.8 60.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.531 179.974 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 1.026 HD13 ' N ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -61.78 -18.58 60.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.251 -179.978 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 1.026 ' N ' HD13 ' A' ' 132' ' ' LEU . . . -39.82 -28.06 0.13 Allowed Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.696 ' O ' HG22 ' A' ' 137' ' ' ILE . 1.8 t -67.11 -45.11 78.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.753 0.311 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 132' ' ' LEU . 1.4 mt -66.28 -19.8 65.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.629 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 tp -63.54 -19.8 65.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.551 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.696 HG22 ' O ' ' A' ' 134' ' ' SER . 16.7 tt -67.31 -21.0 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.454 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.4 -23.87 40.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.573 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -41.05 -30.3 0.38 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 87.6 m -65.5 -56.47 12.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.3 mm -64.14 -29.84 48.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.492 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 99.0 m -61.09 -20.19 62.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.569 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 p -41.92 158.16 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.584 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.416 ' H ' HG22 ' A' ' 144' ' ' THR . 0.1 OUTLIER -46.04 112.86 0.53 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.571 179.939 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.446 ' H ' ' HD2' ' A' ' 146' ' ' PRO . 0.1 OUTLIER 178.72 -50.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.896 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.446 ' HD2' ' H ' ' A' ' 145' ' ' ASP . 73.1 Cg_endo -83.0 176.1 7.91 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 122.28 1.987 . . . . 0.0 112.22 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 147' ' ' VAL . 31.1 m -42.56 119.6 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.604 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -69.07 -19.93 64.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.526 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.78 -24.23 34.56 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.57 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.16 -24.03 66.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.615 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 39.0 tp -69.86 -32.42 70.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.469 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 87.6 mt -71.43 -68.54 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.523 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 54.9 t -55.14 115.64 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.564 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.682 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.473 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 2.8 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.744 0.307 . . . . 0.0 110.487 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.473 ' CD2' ' O ' ' A' ' 125' ' ' LEU . 91.1 m-85 -156.24 60.52 2.35 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.638 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.83 179.0 6.09 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.714 2.276 . . . . 0.0 112.143 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -51.61 -69.99 0.1 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.6 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.649 ' O ' HG23 ' A' ' 129' ' ' ILE . 4.6 tt -83.01 81.16 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.559 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -68.36 -20.04 64.68 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.497 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -61.03 -65.68 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.61 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.5 ' O ' ' N ' ' A' ' 134' ' ' SER . 1.2 tt -62.14 -56.03 22.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.577 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -41.4 -21.86 0.07 OUTLIER Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.501 ' OG ' ' N ' ' A' ' 135' ' ' LEU . 6.2 p -66.86 -60.03 3.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.63 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.501 ' N ' ' OG ' ' A' ' 134' ' ' SER . 1.1 tp -66.17 -23.79 66.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.589 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 tp -64.34 -53.44 48.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.59 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 86.1 mt -67.84 -28.79 42.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.538 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.0 -23.65 34.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.637 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.481 ' O ' HG22 ' A' ' 142' ' ' THR . . . -79.04 -22.97 64.63 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 68.5 m -65.74 -20.97 66.47 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.806 0.336 . . . . 0.0 110.608 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.556 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -64.08 -29.18 46.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.593 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . 0.481 HG22 ' O ' ' A' ' 139' ' ' GLY . 2.4 t -60.94 -26.88 67.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.605 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . 0.403 ' O ' ' O ' ' A' ' 144' ' ' THR . 0.7 OUTLIER -99.36 -162.1 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.598 -179.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.403 ' O ' ' O ' ' A' ' 143' ' ' SER . 16.3 p 55.17 106.98 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.477 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.449 ' CB ' ' CD ' ' A' ' 146' ' ' PRO . 0.9 OUTLIER -175.27 -64.73 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.937 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 145' ' ' ASP . 16.8 Cg_endo -58.48 170.11 2.67 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.168 1.912 . . . . 0.0 112.034 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.676 ' O ' HG22 ' A' ' 147' ' ' VAL . 7.2 p -90.83 5.01 5.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.572 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 tp -69.19 -39.78 78.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.429 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 93.2 p -55.7 -44.83 77.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.546 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.1 -27.06 67.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.501 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.496 HD23 ' O ' ' A' ' 151' ' ' LEU . 1.1 tt -69.91 -55.34 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.598 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 5.1 mt -71.42 -20.07 20.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.553 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.59 HG12 ' H ' ' A' ' 154' ' ' GLY . 2.6 t 63.31 -135.45 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.562 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.59 ' H ' HG12 ' A' ' 153' ' ' VAL . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.81 0.338 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.505 ' N ' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER 178.72 -47.15 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 179.76 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.505 ' CD ' ' N ' ' A' ' 126' ' ' PHE . 32.8 Cg_exo -56.68 -149.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 122.23 1.953 . . . . 0.0 112.117 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -62.78 -19.8 64.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 46.8 mt -50.03 -28.98 4.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.554 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -68.23 -46.28 70.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.479 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -61.03 -21.08 63.27 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.452 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.12 -31.82 72.33 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.457 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -70.32 -29.0 70.56 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.94 -31.43 72.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.741 0.305 . . . . 0.0 110.535 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -21.62 66.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.417 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.26 -58.63 6.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.47 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 14.2 pt -67.85 -30.06 47.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.524 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -55.98 -21.57 21.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.536 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.15 -20.11 6.37 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 7.8 p -65.81 -19.97 66.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.788 0.327 . . . . 0.0 110.549 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.796 HG22 ' O ' ' A' ' 138' ' ' ALA . 15.9 tt -64.07 -27.08 41.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.618 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 81.0 p -61.02 -20.11 62.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.58 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.7 t -42.93 -91.6 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.578 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 27.6 p -141.34 -108.91 0.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.523 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 30.8 m-20 -155.5 60.11 2.41 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' O ' ' N ' ' A' ' 148' ' ' LEU . 55.3 Cg_endo -73.56 -167.54 0.38 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.715 2.277 . . . . 0.0 112.055 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 147' ' ' VAL . 7.5 p -45.59 94.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.532 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.448 ' N ' ' O ' ' A' ' 146' ' ' PRO . 1.0 OUTLIER -68.99 -20.12 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.564 -179.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.87 -20.75 16.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.523 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.99 -33.83 76.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.584 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.1 tp -69.82 -27.06 64.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.561 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 1.3 mm -71.55 -43.68 71.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.427 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.514 HG12 ' O ' ' A' ' 153' ' ' VAL . 97.2 t -62.0 -8.46 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.579 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.696 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 179.997 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 9.9 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.79 0.329 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.439 ' CD1' ' N ' ' A' ' 126' ' ' PHE . 2.1 p90 -152.87 67.26 6.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.589 179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.8 133.66 22.37 Favored 'Trans proline' 0 C--N 1.305 -1.751 0 C-N-CA 122.816 2.344 . . . . 0.0 112.076 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -79.26 -51.36 9.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.494 179.99 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.717 ' O ' HG23 ' A' ' 129' ' ' ILE . 16.8 tt -51.64 101.92 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.519 179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -68.37 -19.91 64.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.626 179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -60.82 -69.91 0.21 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.627 179.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.2 tp -62.1 -31.64 72.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.569 179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.15 -34.97 3.41 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.955 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 137' ' ' ILE . 11.4 t -66.99 -47.06 72.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.741 0.305 . . . . 0.0 110.498 -179.951 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.3 tt -66.12 -26.27 67.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.552 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 tp -64.34 -20.24 65.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.548 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.502 HG22 ' O ' ' A' ' 134' ' ' SER . 6.7 tt -67.81 -20.05 25.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.555 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.09 -21.32 21.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -81.62 -25.88 52.3 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.65 -23.38 66.79 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.804 0.335 . . . . 0.0 110.547 -179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.551 ' N ' HD12 ' A' ' 141' ' ' ILE . 1.7 mp -63.96 -32.59 57.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.565 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 7.7 m -61.16 -31.88 71.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.507 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 1.3 t 172.42 132.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.561 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 145' ' ' ASP . 0.9 OUTLIER -87.78 102.66 14.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.52 -179.964 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 144' ' ' THR . 0.8 OUTLIER -30.46 95.57 0.08 OUTLIER Pre-proline 0 CA--C 1.534 0.36 0 O-C-N 123.768 0.668 . . . . 0.0 111.514 -179.883 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -54.52 119.02 5.72 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.11 1.874 . . . . 0.0 111.863 179.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 11.9 t -87.2 98.81 7.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.587 179.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 1.5 mp -69.34 -29.07 66.8 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.581 179.919 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.86 -29.83 60.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.634 -179.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.95 -40.74 91.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.571 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.78 -42.85 73.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.566 179.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 72.1 mt -71.45 -58.1 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.553 179.981 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 36.8 t -101.7 136.11 35.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.543 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.98 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.496 ' CG ' ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.793 0.33 . . . . 0.0 110.586 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.496 ' H ' ' CG ' ' A' ' 125' ' ' LEU . 71.5 m-85 -138.8 60.74 19.82 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.649 179.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.432 ' O ' ' N ' ' A' ' 129' ' ' ILE . 55.9 Cg_endo -74.09 -168.05 0.44 Allowed 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 122.683 2.256 . . . . 0.0 112.086 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.519 ' CD ' ' H ' ' A' ' 128' ' ' GLN . 7.5 mp0 -41.98 -25.45 0.06 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.556 179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.536 HG22 ' HB2' ' A' ' 132' ' ' LEU . 18.7 mt -74.52 40.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.553 179.994 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.438 ' H ' ' C ' ' A' ' 128' ' ' GLN . 0.5 OUTLIER -68.31 -20.2 64.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.546 179.986 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -60.88 -33.93 73.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.562 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.536 ' HB2' HG22 ' A' ' 129' ' ' ILE . 1.4 mt -62.2 -42.1 98.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.486 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -73.47 -21.91 79.09 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.2 t -66.94 -25.99 66.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -66.12 -26.52 67.49 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.492 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.0 mt -64.35 -48.17 76.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.533 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 2.6 mt -67.81 -43.11 86.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.662 179.941 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.02 -22.81 29.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.545 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -82.67 -27.02 43.97 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -22.77 66.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.554 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 9.2 mm -64.14 -22.76 31.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.509 -179.905 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 70.5 p -60.98 -23.02 65.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.585 179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.8 t -73.36 52.98 0.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.511 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -98.14 -47.3 5.54 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.588 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -145.0 67.12 13.27 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.532 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.467 ' C ' ' H ' ' A' ' 148' ' ' LEU . 52.0 Cg_exo -47.64 179.97 0.01 OUTLIER 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.809 2.34 . . . . 0.0 112.199 179.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.433 ' H ' HG23 ' A' ' 147' ' ' VAL . 0.2 OUTLIER -61.99 -0.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.514 -179.997 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.467 ' H ' ' C ' ' A' ' 146' ' ' PRO . 0.1 OUTLIER -69.04 -49.63 55.83 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.423 179.997 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.95 -19.98 14.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.629 179.897 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.475 ' O ' ' CG2' ' A' ' 153' ' ' VAL . . . -65.95 -25.0 66.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.655 179.913 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -70.22 -57.26 5.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.505 ' C ' HG23 ' A' ' 153' ' ' VAL . 5.7 mt -71.46 -65.6 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.623 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.505 HG23 ' C ' ' A' ' 152' ' ' ILE . 2.1 t 66.3 153.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.603 -179.92 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.982 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 mp . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.805 0.336 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.418 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 68.4 t80 44.63 60.74 12.28 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.617 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.11 131.77 15.84 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 122.674 2.249 . . . . 0.0 112.055 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -63.17 -43.43 98.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.533 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.2 mt -55.33 99.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.562 -179.985 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -68.34 -22.86 64.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.591 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -60.91 -31.68 71.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.655 179.888 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.06 -26.0 68.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.57 179.925 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -68.11 -37.53 87.25 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.88 -27.55 67.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.802 0.334 . . . . 0.0 110.561 -179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 2.9 mp -66.01 -21.47 66.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.551 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.472 HD23 ' O ' ' A' ' 136' ' ' LEU . 1.2 tt -64.36 -57.96 7.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.645 -179.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 8.3 mt -67.91 -60.66 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.584 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' ILE . . . -56.01 -23.88 35.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.515 -179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -52.27 -25.69 19.56 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.71 -20.06 66.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.785 0.326 . . . . 0.0 110.554 179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' ALA . 1.2 tp -64.1 -23.41 33.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.579 -179.996 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 72.5 m -61.03 -66.84 0.47 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.594 179.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.0 m 42.75 77.07 0.07 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.589 179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -138.31 -30.49 0.78 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.573 179.964 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 147' ' ' VAL . 48.1 t0 -145.45 60.53 6.87 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.567 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.85 20.16 0.39 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.753 2.302 . . . . 0.0 112.174 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.705 HG12 ' O ' ' A' ' 147' ' ' VAL . 61.2 t -77.08 48.69 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.606 179.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 3.1 mt -69.03 -20.38 64.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.564 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -55.93 -35.89 67.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.597 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.0 -20.17 66.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.59 179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 151' ' ' LEU . 1.2 tt -69.74 -57.87 4.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.55 -179.969 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 13.7 mt -71.44 -39.21 70.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.511 -179.909 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.44 142.57 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.628 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.978 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 126' ' ' PHE . 2.3 tp . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.769 0.319 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.483 ' H ' HD23 ' A' ' 125' ' ' LEU . 22.7 t80 -163.98 62.79 1.08 Allowed Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.623 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -75.7 -165.32 0.29 Allowed 'Trans proline' 0 C--N 1.306 -1.701 0 C-N-CA 122.691 2.26 . . . . 0.0 112.2 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -82.48 -48.77 10.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.782 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.424 ' C ' HD12 ' A' ' 129' ' ' ILE . 1.0 OUTLIER -85.16 32.2 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.095 0.474 . . . . 0.0 110.59 179.997 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -68.15 -25.88 65.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -60.97 -50.46 73.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.615 179.919 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 2.3 tp -62.05 -27.26 68.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -64.81 -31.11 79.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -49.93 64.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.573 -179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 35.4 mt -66.16 -28.52 68.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.564 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -64.37 -51.31 63.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.583 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 69.3 mt -67.9 -44.41 85.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.564 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.88 61.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.563 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -78.78 -20.18 71.5 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -65.81 -28.21 68.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.751 0.31 . . . . 0.0 110.552 179.941 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 77.7 mt -64.08 -20.91 27.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.486 -179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 59.4 m -60.92 -66.75 0.48 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.596 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 9.7 p -87.18 139.55 30.45 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.525 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER 65.89 159.77 0.12 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.494 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -150.59 60.54 4.17 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.653 -179.917 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.94 148.65 40.83 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 C-N-CA 122.795 2.33 . . . . 0.0 112.045 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . . . . . . . . . 35.1 m -99.73 -18.32 6.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.61 179.955 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.11 -63.66 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.597 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.487 ' O ' HG22 ' A' ' 152' ' ' ILE . 75.3 m -55.93 -29.87 60.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.934 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.06 -20.03 66.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.555 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 1.8 tp -69.81 -19.96 63.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.493 -179.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . 0.487 HG22 ' O ' ' A' ' 149' ' ' SER . 1.9 tp -71.42 -20.91 21.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.521 -179.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 5.4 p -43.79 151.39 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.593 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.628 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 179.965 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.809 0.337 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.411 ' O ' ' CD2' ' A' ' 126' ' ' PHE . 75.1 t80 -162.3 67.23 1.97 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.589 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.79 111.32 0.41 Allowed 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.806 2.337 . . . . 0.0 112.071 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -84.92 -20.08 31.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.52 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.6 pt -56.41 137.57 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.611 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -68.35 -20.06 64.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.59 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -60.86 -65.72 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.607 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 1.1 tp -62.09 -22.35 65.72 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.556 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -55.1 -21.67 25.78 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.3 p -66.92 -23.62 66.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.759 0.314 . . . . 0.0 110.559 -179.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 1.9 tp -66.14 -35.41 80.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.518 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -64.3 -42.5 96.33 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.598 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.2 mm -67.85 -37.45 78.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.54 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ALA . . . . . 0.423 ' C ' ' N ' ' A' ' 140' ' ' CYS . . . -56.0 -25.67 45.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.535 -179.995 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -43.13 -23.05 0.21 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' CYS . . . . . 0.423 ' N ' ' C ' ' A' ' 138' ' ' ALA . 4.2 t -65.7 -42.87 90.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.796 0.332 . . . . 0.0 110.574 179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 84.3 mt -64.12 -42.23 94.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' THR . . . . . . . . . . . . . 19.0 p -61.01 -22.5 64.59 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.577 -179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.5 t 60.99 78.24 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.581 179.994 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' THR . . . . . . . . . . . . . 1.7 t -172.23 150.33 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.503 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 43.23 67.25 3.81 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.593 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -47.76 137.67 21.02 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 C-N-CA 122.773 2.315 . . . . 0.0 112.123 -179.981 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 148' ' ' LEU . 63.3 t -77.01 154.77 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.606 179.96 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.465 ' N ' HD12 ' A' ' 148' ' ' LEU . 10.8 mp -69.07 -46.17 68.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.59 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . 0.426 ' H ' HG12 ' A' ' 147' ' ' VAL . 0.6 OUTLIER -55.94 -43.84 77.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.548 179.959 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.11 -22.73 66.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.542 -179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' LEU . . . . . . . . . . . . . 2.0 tp -69.87 -22.6 63.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.528 -179.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' ILE . . . . . . . . . . . . . 31.7 mt -71.47 -64.51 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.574 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -138.09 145.28 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.569 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.99 . . . . . . . . 0 0 . 1 stop_ save_